https://trial.medpath.com/news/caring-cross-partners-with-amrita-research-center-to-develop-affordable-car-t-and-gene-therapies-for-underserved-indian-populations 2025-11-25T17:26:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/caring-cross-partners-with-amrita-research-center-to-develop-affordable-car-t-and-gene-therapies-for-underserved-indian-populations 2025-11-25T17:26:29+00:00 hourly 0.9 https://trial.medpath.com/news/tyrosine-kinase-inhibitors-and-gene-therapies-show-promise-for-wet-amd-treatment 2025-11-25T17:26:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tyrosine-kinase-inhibitors-and-gene-therapies-show-promise-for-wet-amd-treatment 2025-11-25T17:26:13+00:00 hourly 0.9 https://trial.medpath.com/news/fda-expands-max-3tm-syringeless-mri-injector-for-use-with-vueway-r-imaging-bulk-package 2025-11-25T17:24:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-expands-max-3tm-syringeless-mri-injector-for-use-with-vueway-r-imaging-bulk-package 2025-11-25T17:24:05+00:00 hourly 0.9 https://trial.medpath.com/news/precisionlife-and-ovation-partner-to-develop-precision-medicine-test-for-glp-1-drug-reimbursement 2025-11-25T17:23:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/precisionlife-and-ovation-partner-to-develop-precision-medicine-test-for-glp-1-drug-reimbursement 2025-11-25T17:23:45+00:00 hourly 0.9 https://trial.medpath.com/news/kelun-s-trop2-targeted-adc-shows-promise-in-first-line-lung-cancer-trial 2025-11-25T17:23:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kelun-s-trop2-targeted-adc-shows-promise-in-first-line-lung-cancer-trial 2025-11-25T17:23:03+00:00 hourly 0.9 https://trial.medpath.com/news/pasithea-therapeutics-receives-1-million-als-association-grant-to-advance-pas-004-mek-inhibitor-in-phase-1-als-trial 2025-11-25T13:26:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pasithea-therapeutics-receives-1-million-als-association-grant-to-advance-pas-004-mek-inhibitor-in-phase-1-als-trial 2025-11-25T13:26:26+00:00 hourly 0.9 https://trial.medpath.com/news/nice-recommends-aucatzyl-car-t-therapy-for-adult-relapsed-refractory-b-cell-all-in-england-and-wales 2025-11-25T13:25:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nice-recommends-aucatzyl-car-t-therapy-for-adult-relapsed-refractory-b-cell-all-in-england-and-wales 2025-11-25T13:25:42+00:00 hourly 0.9 https://trial.medpath.com/news/active-biotech-secures-us-patent-for-tasquinimod-formulation-extending-market-exclusivity-to-2042 2025-11-25T13:24:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/active-biotech-secures-us-patent-for-tasquinimod-formulation-extending-market-exclusivity-to-2042 2025-11-25T13:24:34+00:00 hourly 0.9 https://trial.medpath.com/news/biomed-x-and-abbvie-launch-neuroscience-collaboration-to-target-anhedonia-mechanisms 2025-11-25T09:33:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biomed-x-and-abbvie-launch-neuroscience-collaboration-to-target-anhedonia-mechanisms 2025-11-25T09:33:19+00:00 hourly 0.9 https://trial.medpath.com/news/ai-powered-launch-intelligence-transforms-pharmaceutical-market-entry-strategy 2025-11-25T07:47:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ai-powered-launch-intelligence-transforms-pharmaceutical-market-entry-strategy 2025-11-25T07:47:31+00:00 hourly 0.9 https://trial.medpath.com/news/european-commission-approves-dupixent-as-first-line-targeted-therapy-for-chronic-spontaneous-urticaria 2025-11-25T06:19:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/european-commission-approves-dupixent-as-first-line-targeted-therapy-for-chronic-spontaneous-urticaria 2025-11-25T06:19:00+00:00 hourly 0.9 https://trial.medpath.com/news/ascentage-pharma-s-olverembatinib-shows-23-1-response-rate-in-rare-gist-subtype-with-novel-lipid-metabolism-mechanism 2025-11-25T05:26:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ascentage-pharma-s-olverembatinib-shows-23-1-response-rate-in-rare-gist-subtype-with-novel-lipid-metabolism-mechanism 2025-11-25T05:26:22+00:00 hourly 0.9 https://trial.medpath.com/news/verrica-pharmaceuticals-secures-50-million-financing-to-advance-dermatology-pipeline-and-eliminate-debt 2025-11-25T05:26:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/verrica-pharmaceuticals-secures-50-million-financing-to-advance-dermatology-pipeline-and-eliminate-debt 2025-11-25T05:26:03+00:00 hourly 0.9 https://trial.medpath.com/news/otsuka-submits-fda-application-for-first-in-class-adhd-drug-centanafadine 2025-11-25T05:22:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/otsuka-submits-fda-application-for-first-in-class-adhd-drug-centanafadine 2025-11-25T05:22:50+00:00 hourly 0.9 https://trial.medpath.com/news/nhs-approves-breakthrough-car-t-therapy-obe-cel-for-aggressive-leukemia-with-77-remission-rate 2025-11-25T05:22:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nhs-approves-breakthrough-car-t-therapy-obe-cel-for-aggressive-leukemia-with-77-remission-rate 2025-11-25T05:22:15+00:00 hourly 0.9 https://trial.medpath.com/news/glp-1-discontinuation-before-pregnancy-linked-to-increased-weight-gain-and-complications 2025-11-25T01:28:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/glp-1-discontinuation-before-pregnancy-linked-to-increased-weight-gain-and-complications 2025-11-25T01:28:54+00:00 hourly 0.9 https://trial.medpath.com/news/overweight-multiple-myeloma-patients-show-worse-outcomes-with-anti-bcma-car-t-therapy-in-u-shaped-bmi-pattern 2025-11-25T01:27:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/overweight-multiple-myeloma-patients-show-worse-outcomes-with-anti-bcma-car-t-therapy-in-u-shaped-bmi-pattern 2025-11-25T01:27:33+00:00 hourly 0.9 https://trial.medpath.com/news/calcium-activated-switch-enhances-antibody-drug-conjugate-delivery-and-potency-in-cancer-treatment 2025-11-25T01:26:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/calcium-activated-switch-enhances-antibody-drug-conjugate-delivery-and-potency-in-cancer-treatment 2025-11-25T01:26:50+00:00 hourly 0.9 https://trial.medpath.com/news/praxis-precision-medicines-to-showcase-epilepsy-pipeline-at-aes-2025-with-full-radiant-study-results 2025-11-25T01:24:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/praxis-precision-medicines-to-showcase-epilepsy-pipeline-at-aes-2025-with-full-radiant-study-results 2025-11-25T01:24:33+00:00 hourly 0.9 https://trial.medpath.com/news/artera-s-ai-model-shows-promise-for-personalizing-breast-cancer-treatment-decisions 2025-11-25T01:24:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/artera-s-ai-model-shows-promise-for-personalizing-breast-cancer-treatment-decisions 2025-11-25T01:24:30+00:00 hourly 0.9 https://trial.medpath.com/news/bristol-myers-squibb-receives-european-commission-approval-for-breyanzi-in-relapsed-refractory-mantle-cell-lymphoma 2025-11-25T01:23:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bristol-myers-squibb-receives-european-commission-approval-for-breyanzi-in-relapsed-refractory-mantle-cell-lymphoma 2025-11-25T01:23:49+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-first-intrathecal-gene-therapy-for-spinal-muscular-atrophy-across-all-ages 2025-11-25T01:23:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-first-intrathecal-gene-therapy-for-spinal-muscular-atrophy-across-all-ages 2025-11-25T01:23:17+00:00 hourly 0.9 https://trial.medpath.com/news/aidoc-achieves-fda-clearance-for-healthcare-s-first-comprehensive-foundation-model-ai-triage-solution 2025-11-25T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aidoc-achieves-fda-clearance-for-healthcare-s-first-comprehensive-foundation-model-ai-triage-solution 2025-11-25T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/thermo-fisher-scientific-opens-advanced-therapies-collaboration-center-in-philadelphia-to-accelerate-cell-and-gene-therapy-development 2025-11-24T22:42:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/thermo-fisher-scientific-opens-advanced-therapies-collaboration-center-in-philadelphia-to-accelerate-cell-and-gene-therapy-development 2025-11-24T22:42:00+00:00 hourly 0.9 https://trial.medpath.com/news/enquyst-technologies-achieves-breakthrough-in-monoclonal-antibody-manufacturing-with-chromatography-free-purification-platform 2025-11-24T21:26:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/enquyst-technologies-achieves-breakthrough-in-monoclonal-antibody-manufacturing-with-chromatography-free-purification-platform 2025-11-24T21:26:08+00:00 hourly 0.9 https://trial.medpath.com/news/kelonia-s-in-vivo-car-t-therapy-shows-promising-early-results-in-multiple-myeloma-patients 2025-11-24T21:25:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kelonia-s-in-vivo-car-t-therapy-shows-promising-early-results-in-multiple-myeloma-patients 2025-11-24T21:25:19+00:00 hourly 0.9 https://trial.medpath.com/news/ucla-receives-6-7-million-grant-to-expand-groundbreaking-kidney-transplant-trial-that-eliminates-immunosuppressive-drugs 2025-11-24T21:21:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ucla-receives-6-7-million-grant-to-expand-groundbreaking-kidney-transplant-trial-that-eliminates-immunosuppressive-drugs 2025-11-24T21:21:26+00:00 hourly 0.9 https://trial.medpath.com/news/adaptive-biotechnologies-clonoseq-mrd-test-featured-in-record-89-abstracts-at-ash-2025 2025-11-24T17:41:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/adaptive-biotechnologies-clonoseq-mrd-test-featured-in-record-89-abstracts-at-ash-2025 2025-11-24T17:41:35+00:00 hourly 0.9 https://trial.medpath.com/news/day-one-reports-three-year-ojemda-data-shows-sustained-treatment-free-periods-in-pediatric-brain-cancer 2025-11-24T17:41:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/day-one-reports-three-year-ojemda-data-shows-sustained-treatment-free-periods-in-pediatric-brain-cancer 2025-11-24T17:41:13+00:00 hourly 0.9 https://trial.medpath.com/news/capricor-therapeutics-advances-exosome-drug-delivery-with-scalable-manufacturing-framework 2025-11-24T17:39:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/capricor-therapeutics-advances-exosome-drug-delivery-with-scalable-manufacturing-framework 2025-11-24T17:39:28+00:00 hourly 0.9 https://trial.medpath.com/news/dana-farber-presents-breakthrough-findings-in-blood-cancer-treatment-at-ash-2025 2025-11-24T17:38:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dana-farber-presents-breakthrough-findings-in-blood-cancer-treatment-at-ash-2025 2025-11-24T17:38:14+00:00 hourly 0.9 https://trial.medpath.com/news/menarini-group-to-present-new-elzonris-data-at-ash-2025-including-promising-triplet-therapy-results-for-bpdcn 2025-11-24T17:36:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/menarini-group-to-present-new-elzonris-data-at-ash-2025-including-promising-triplet-therapy-results-for-bpdcn 2025-11-24T17:36:18+00:00 hourly 0.9 https://trial.medpath.com/news/harmony-biosciences-reports-positive-bioequivalence-results-for-pitolisant-gr-formulation-plans-2026-nda-submission 2025-11-24T17:35:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/harmony-biosciences-reports-positive-bioequivalence-results-for-pitolisant-gr-formulation-plans-2026-nda-submission 2025-11-24T17:35:06+00:00 hourly 0.9 https://trial.medpath.com/news/invivyd-selects-vby329-as-potential-best-in-class-rsv-antibody-for-pediatric-prevention 2025-11-24T17:34:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/invivyd-selects-vby329-as-potential-best-in-class-rsv-antibody-for-pediatric-prevention 2025-11-24T17:34:52+00:00 hourly 0.9 https://trial.medpath.com/news/adia-nutrition-submits-patent-pending-autism-protocol-for-irb-review-advancing-stem-cell-therapy-study 2025-11-24T17:34:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/adia-nutrition-submits-patent-pending-autism-protocol-for-irb-review-advancing-stem-cell-therapy-study 2025-11-24T17:34:16+00:00 hourly 0.9 https://trial.medpath.com/news/vertero-therapeutics-launches-phase-1-trial-of-vt-5006-first-in-class-gut-selective-therapy-for-parkinson-s-disease 2025-11-24T17:31:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vertero-therapeutics-launches-phase-1-trial-of-vt-5006-first-in-class-gut-selective-therapy-for-parkinson-s-disease 2025-11-24T17:31:18+00:00 hourly 0.9 https://trial.medpath.com/news/amorphical-enrolls-first-patient-in-phase-2-trial-testing-novel-nano-amorphous-mineral-therapy-for-stage-iv-pancreatic-cancer 2025-11-24T17:31:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/amorphical-enrolls-first-patient-in-phase-2-trial-testing-novel-nano-amorphous-mineral-therapy-for-stage-iv-pancreatic-cancer 2025-11-24T17:31:12+00:00 hourly 0.9 https://trial.medpath.com/news/thiogenesis-therapeutics-plans-phase-3-trial-for-next-generation-cystinosis-treatment-tti-0102 2025-11-24T17:28:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/thiogenesis-therapeutics-plans-phase-3-trial-for-next-generation-cystinosis-treatment-tti-0102 2025-11-24T17:28:55+00:00 hourly 0.9 https://trial.medpath.com/news/jyong-biotech-signs-letter-of-intent-for-mcs-2-licensing-in-south-korea 2025-11-24T17:28:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/jyong-biotech-signs-letter-of-intent-for-mcs-2-licensing-in-south-korea 2025-11-24T17:28:46+00:00 hourly 0.9 https://trial.medpath.com/news/can-fite-seeks-veterinary-partnerships-for-cancer-drug-namodenoson-at-biofit-2025 2025-11-24T17:27:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/can-fite-seeks-veterinary-partnerships-for-cancer-drug-namodenoson-at-biofit-2025 2025-11-24T17:27:06+00:00 hourly 0.9 https://trial.medpath.com/news/heidelberg-pharma-appoints-dr-dongzhou-jeffery-liu-as-new-ceo-amid-leadership-transition 2025-11-24T17:27:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/heidelberg-pharma-appoints-dr-dongzhou-jeffery-liu-as-new-ceo-amid-leadership-transition 2025-11-24T17:27:00+00:00 hourly 0.9 https://trial.medpath.com/news/biogen-partners-with-dayra-therapeutics-in-50-million-deal-to-develop-oral-macrocyclic-peptides-for-immunological-conditions 2025-11-24T17:26:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biogen-partners-with-dayra-therapeutics-in-50-million-deal-to-develop-oral-macrocyclic-peptides-for-immunological-conditions 2025-11-24T17:26:51+00:00 hourly 0.9 https://trial.medpath.com/news/oral-semaglutide-fails-to-slow-alzheimer-s-disease-progression-in-phase-3-trials 2025-11-24T17:26:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oral-semaglutide-fails-to-slow-alzheimer-s-disease-progression-in-phase-3-trials 2025-11-24T17:26:24+00:00 hourly 0.9 https://trial.medpath.com/news/in-vivo-car-t-therapies-drive-6-1-billion-in-biotech-acquisitions-as-investors-shift-from-traditional-cell-therapy-approaches 2025-11-24T17:26:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/in-vivo-car-t-therapies-drive-6-1-billion-in-biotech-acquisitions-as-investors-shift-from-traditional-cell-therapy-approaches 2025-11-24T17:26:13+00:00 hourly 0.9 https://trial.medpath.com/news/merck-s-cladribine-capsules-receive-fda-fast-track-designation-for-rare-neuromuscular-disorder 2025-11-24T17:26:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/merck-s-cladribine-capsules-receive-fda-fast-track-designation-for-rare-neuromuscular-disorder 2025-11-24T17:26:10+00:00 hourly 0.9 https://trial.medpath.com/news/ocular-therapeutix-initiates-helios-3-phase-3-trial-for-axpaxli-in-diabetic-retinopathy 2025-11-24T17:25:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ocular-therapeutix-initiates-helios-3-phase-3-trial-for-axpaxli-in-diabetic-retinopathy 2025-11-24T17:25:29+00:00 hourly 0.9 https://trial.medpath.com/news/ropeginterferon-alfa-2b-shows-superior-efficacy-over-anagrelide-in-phase-3-essential-thrombocythemia-trial 2025-11-24T17:24:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ropeginterferon-alfa-2b-shows-superior-efficacy-over-anagrelide-in-phase-3-essential-thrombocythemia-trial 2025-11-24T17:24:40+00:00 hourly 0.9 https://trial.medpath.com/news/johnson-johnson-s-posdinemab-fails-phase-2b-trial-dealing-blow-to-tau-targeting-alzheimer-s-therapies 2025-11-24T17:23:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/johnson-johnson-s-posdinemab-fails-phase-2b-trial-dealing-blow-to-tau-targeting-alzheimer-s-therapies 2025-11-24T17:23:44+00:00 hourly 0.9 https://trial.medpath.com/news/circular-genomics-unveils-blood-based-circular-rna-biomarkers-for-early-alzheimer-s-disease-detection 2025-11-24T17:23:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/circular-genomics-unveils-blood-based-circular-rna-biomarkers-for-early-alzheimer-s-disease-detection 2025-11-24T17:23:35+00:00 hourly 0.9 https://trial.medpath.com/news/versant-ventures-launches-dayra-therapeutics-with-70m-funding-and-biogen-partnership-for-oral-macrocyclic-peptides 2025-11-24T17:22:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/versant-ventures-launches-dayra-therapeutics-with-70m-funding-and-biogen-partnership-for-oral-macrocyclic-peptides 2025-11-24T17:22:27+00:00 hourly 0.9 https://trial.medpath.com/news/neurosense-receives-fda-clearance-for-pivotal-phase-3-trial-of-primec-in-als 2025-11-24T17:22:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/neurosense-receives-fda-clearance-for-pivotal-phase-3-trial-of-primec-in-als 2025-11-24T17:22:07+00:00 hourly 0.9 https://trial.medpath.com/news/tumor-associated-macrophages-drive-gastric-cancer-progression-through-immune-evasion-and-therapeutic-resistance 2025-11-24T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tumor-associated-macrophages-drive-gastric-cancer-progression-through-immune-evasion-and-therapeutic-resistance 2025-11-24T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/century-old-diabetes-drug-metformin-reduces-insulin-requirements-in-type-1-diabetes-patients 2025-11-24T13:25:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/century-old-diabetes-drug-metformin-reduces-insulin-requirements-in-type-1-diabetes-patients 2025-11-24T13:25:10+00:00 hourly 0.9 https://trial.medpath.com/news/mrna-technology-shows-promise-for-preventing-muscle-damage-from-snakebites 2025-11-24T13:25:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mrna-technology-shows-promise-for-preventing-muscle-damage-from-snakebites 2025-11-24T13:25:02+00:00 hourly 0.9 https://trial.medpath.com/news/vaximm-secures-potential-835m-deal-with-bcm-europe-for-oral-cancer-immunotherapy-platform-vxm01 2025-11-24T13:24:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vaximm-secures-potential-835m-deal-with-bcm-europe-for-oral-cancer-immunotherapy-platform-vxm01 2025-11-24T13:24:59+00:00 hourly 0.9 https://trial.medpath.com/news/genenta-science-reports-sustained-survival-benefits-in-glioblastoma-trial-with-temferon-cell-therapy 2025-11-24T13:24:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/genenta-science-reports-sustained-survival-benefits-in-glioblastoma-trial-with-temferon-cell-therapy 2025-11-24T13:24:03+00:00 hourly 0.9 https://trial.medpath.com/news/pin-therapeutics-begins-first-in-human-trial-of-ck1a-degrader-pin-5018-for-rare-adenoid-cystic-carcinoma 2025-11-24T13:24:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pin-therapeutics-begins-first-in-human-trial-of-ck1a-degrader-pin-5018-for-rare-adenoid-cystic-carcinoma 2025-11-24T13:24:00+00:00 hourly 0.9 https://trial.medpath.com/news/ananda-pharma-exits-public-markets-and-nhs-epilepsy-trial-to-focus-on-pain-treatment-pipeline 2025-11-24T13:23:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ananda-pharma-exits-public-markets-and-nhs-epilepsy-trial-to-focus-on-pain-treatment-pipeline 2025-11-24T13:23:37+00:00 hourly 0.9 https://trial.medpath.com/news/abbott-laboratories-to-acquire-exact-sciences-for-21-billion-in-major-cancer-diagnostics-consolidation 2025-11-24T13:23:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/abbott-laboratories-to-acquire-exact-sciences-for-21-billion-in-major-cancer-diagnostics-consolidation 2025-11-24T13:23:07+00:00 hourly 0.9 https://trial.medpath.com/news/sequana-medical-achieves-first-u-s-commercial-implantation-of-alfapump-r-system-at-mount-sinai-hospital 2025-11-24T13:22:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sequana-medical-achieves-first-u-s-commercial-implantation-of-alfapump-r-system-at-mount-sinai-hospital 2025-11-24T13:22:25+00:00 hourly 0.9 https://trial.medpath.com/news/fda-cleared-ai-platform-somnum-reduces-sleep-clinical-trial-timelines-by-50 2025-11-24T13:22:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-cleared-ai-platform-somnum-reduces-sleep-clinical-trial-timelines-by-50 2025-11-24T13:22:05+00:00 hourly 0.9 https://trial.medpath.com/news/biocortex-partners-with-cd-biopharma-to-accelerate-precision-immunotherapy-development-using-ai-driven-platform 2025-11-24T13:22:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biocortex-partners-with-cd-biopharma-to-accelerate-precision-immunotherapy-development-using-ai-driven-platform 2025-11-24T13:22:02+00:00 hourly 0.9 https://trial.medpath.com/news/dexamethasone-shows-promise-against-therapy-resistant-breast-cancer-metastases-in-preclinical-studies 2025-11-24T13:21:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dexamethasone-shows-promise-against-therapy-resistant-breast-cancer-metastases-in-preclinical-studies 2025-11-24T13:21:29+00:00 hourly 0.9 https://trial.medpath.com/news/samsung-biologics-completes-strategic-spinoff-to-enhance-biosimilar-and-novel-drug-development 2025-11-24T09:22:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/samsung-biologics-completes-strategic-spinoff-to-enhance-biosimilar-and-novel-drug-development 2025-11-24T09:22:51+00:00 hourly 0.9 https://trial.medpath.com/news/austrian-multicenter-study-demonstrates-hifu-as-effective-organ-preserving-treatment-for-early-prostate-cancer 2025-11-24T09:22:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/austrian-multicenter-study-demonstrates-hifu-as-effective-organ-preserving-treatment-for-early-prostate-cancer 2025-11-24T09:22:46+00:00 hourly 0.9 https://trial.medpath.com/news/fda-regulatory-reversals-disrupt-drug-development-timelines-for-uniqure-biohaven-and-capricor 2025-11-24T09:21:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-regulatory-reversals-disrupt-drug-development-timelines-for-uniqure-biohaven-and-capricor 2025-11-24T09:21:32+00:00 hourly 0.9 https://trial.medpath.com/news/china-s-biotech-sector-emerges-as-key-player-as-big-pharma-faces-300-billion-patent-cliff-through-2030 2025-11-24T08:05:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/china-s-biotech-sector-emerges-as-key-player-as-big-pharma-faces-300-billion-patent-cliff-through-2030 2025-11-24T08:05:38+00:00 hourly 0.9 https://trial.medpath.com/news/triple-negative-breast-cancer-pipeline-expands-with-170-emerging-therapies-across-multiple-development-phases 2025-11-24T07:08:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/triple-negative-breast-cancer-pipeline-expands-with-170-emerging-therapies-across-multiple-development-phases 2025-11-24T07:08:00+00:00 hourly 0.9 https://trial.medpath.com/news/world-first-gene-therapy-shows-remarkable-success-in-three-year-old-with-hunter-syndrome 2025-11-24T05:21:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/world-first-gene-therapy-shows-remarkable-success-in-three-year-old-with-hunter-syndrome 2025-11-24T05:21:49+00:00 hourly 0.9 https://trial.medpath.com/news/harbour-biomed-expands-astrazeneca-partnership-for-next-generation-oncology-therapeutics 2025-11-24T05:21:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/harbour-biomed-expands-astrazeneca-partnership-for-next-generation-oncology-therapeutics 2025-11-24T05:21:18+00:00 hourly 0.9 https://trial.medpath.com/news/geneditbio-and-toolgen-form-strategic-alliance-to-advance-crispr-based-cardiovascular-gene-therapy 2025-11-24T05:21:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/geneditbio-and-toolgen-form-strategic-alliance-to-advance-crispr-based-cardiovascular-gene-therapy 2025-11-24T05:21:10+00:00 hourly 0.9 https://trial.medpath.com/news/hpv-vaccination-shows-dramatic-80-reduction-in-cervical-cancer-risk-when-given-before-age-16 2025-11-24T04:50:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hpv-vaccination-shows-dramatic-80-reduction-in-cervical-cancer-risk-when-given-before-age-16 2025-11-24T04:50:00+00:00 hourly 0.9 https://trial.medpath.com/news/rakovina-therapeutics-presents-ai-discovered-cns-penetrant-atr-mtor-dual-inhibitors-at-neuro-oncology-meeting 2025-11-24T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rakovina-therapeutics-presents-ai-discovered-cns-penetrant-atr-mtor-dual-inhibitors-at-neuro-oncology-meeting 2025-11-24T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/bayer-s-asundexian-shows-promise-in-phase-iii-stroke-prevention-trial-after-2023-setback 2025-11-23T21:22:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bayer-s-asundexian-shows-promise-in-phase-iii-stroke-prevention-trial-after-2023-setback 2025-11-23T21:22:23+00:00 hourly 0.9 https://trial.medpath.com/news/black-cumin-seed-shows-promise-for-cholesterol-management-and-fat-cell-inhibition-in-clinical-trial 2025-11-23T17:20:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/black-cumin-seed-shows-promise-for-cholesterol-management-and-fat-cell-inhibition-in-clinical-trial 2025-11-23T17:20:09+00:00 hourly 0.9 https://trial.medpath.com/news/regulatory-t-cell-therapies-advance-through-clinical-development-with-enhanced-monitoring-technologies 2025-11-23T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/regulatory-t-cell-therapies-advance-through-clinical-development-with-enhanced-monitoring-technologies 2025-11-23T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/novel-bacteriophage-yz2-shows-promise-against-carbapenem-resistant-acinetobacter-baumannii-in-combination-therapy 2025-11-23T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-bacteriophage-yz2-shows-promise-against-carbapenem-resistant-acinetobacter-baumannii-in-combination-therapy 2025-11-23T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/innocan-pharma-s-cbd-delivery-platform-achieves-28-day-sustained-release-in-regulatory-study 2025-11-23T13:22:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/innocan-pharma-s-cbd-delivery-platform-achieves-28-day-sustained-release-in-regulatory-study 2025-11-23T13:22:04+00:00 hourly 0.9 https://trial.medpath.com/news/trikafta-shows-sustained-anti-inflammatory-effects-in-cystic-fibrosis-patients-through-2-5-years 2025-11-23T09:22:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/trikafta-shows-sustained-anti-inflammatory-effects-in-cystic-fibrosis-patients-through-2-5-years 2025-11-23T09:22:34+00:00 hourly 0.9 https://trial.medpath.com/news/gho-capital-partners-acquires-ai-powered-r-d-platform-scientist-com-to-accelerate-pharmaceutical-research-efficiency 2025-11-23T09:21:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gho-capital-partners-acquires-ai-powered-r-d-platform-scientist-com-to-accelerate-pharmaceutical-research-efficiency 2025-11-23T09:21:46+00:00 hourly 0.9 https://trial.medpath.com/news/erdafitinib-shows-promising-early-efficacy-and-manageable-safety-profile-in-fgfr-tacc-fusion-positive-glioma 2025-11-23T09:21:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/erdafitinib-shows-promising-early-efficacy-and-manageable-safety-profile-in-fgfr-tacc-fusion-positive-glioma 2025-11-23T09:21:25+00:00 hourly 0.9 https://trial.medpath.com/news/shilpa-medicare-receives-eight-fda-observations-following-ten-day-inspection-at-jadcherla-manufacturing-facility 2025-11-23T05:20:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/shilpa-medicare-receives-eight-fda-observations-following-ten-day-inspection-at-jadcherla-manufacturing-facility 2025-11-23T05:20:59+00:00 hourly 0.9 https://trial.medpath.com/news/fda-s-new-drug-chief-pazdur-challenges-commissioner-s-expedited-approval-plans 2025-11-23T01:24:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-s-new-drug-chief-pazdur-challenges-commissioner-s-expedited-approval-plans 2025-11-23T01:24:00+00:00 hourly 0.9 https://trial.medpath.com/news/first-in-human-trial-shows-safety-of-intraventricular-her2-car-t-therapy-for-brain-metastases-in-breast-cancer 2025-11-23T01:23:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/first-in-human-trial-shows-safety-of-intraventricular-her2-car-t-therapy-for-brain-metastases-in-breast-cancer 2025-11-23T01:23:09+00:00 hourly 0.9 https://trial.medpath.com/news/lutetium-lu-177-dotatate-demonstrates-significant-efficacy-in-advanced-intracranial-meningioma-phase-2-trial 2025-11-23T01:23:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lutetium-lu-177-dotatate-demonstrates-significant-efficacy-in-advanced-intracranial-meningioma-phase-2-trial 2025-11-23T01:23:07+00:00 hourly 0.9 https://trial.medpath.com/news/scientists-identify-rna-molecule-that-may-reverse-als-nerve-damage-in-preclinical-studies 2025-11-23T01:22:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/scientists-identify-rna-molecule-that-may-reverse-als-nerve-damage-in-preclinical-studies 2025-11-23T01:22:41+00:00 hourly 0.9 https://trial.medpath.com/news/oral-arginine-shows-promise-as-cost-effective-alzheimer-s-treatment-in-preclinical-studies 2025-11-22T21:24:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oral-arginine-shows-promise-as-cost-effective-alzheimer-s-treatment-in-preclinical-studies 2025-11-22T21:24:58+00:00 hourly 0.9 https://trial.medpath.com/news/ajinomoto-partners-with-forge-biologics-to-double-gene-therapy-manufacturing-productivity 2025-11-22T21:23:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ajinomoto-partners-with-forge-biologics-to-double-gene-therapy-manufacturing-productivity 2025-11-22T21:23:29+00:00 hourly 0.9 https://trial.medpath.com/news/cassandra-phase-3-trial-shows-paxg-superior-to-mfolfirinox-in-preoperative-pancreatic-cancer-treatment 2025-11-22T21:21:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cassandra-phase-3-trial-shows-paxg-superior-to-mfolfirinox-in-preoperative-pancreatic-cancer-treatment 2025-11-22T21:21:25+00:00 hourly 0.9 https://trial.medpath.com/news/phase-1-regoma-2-trial-establishes-safe-dosing-for-regorafenib-combination-in-mgmt-methylated-glioblastoma 2025-11-22T17:21:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/phase-1-regoma-2-trial-establishes-safe-dosing-for-regorafenib-combination-in-mgmt-methylated-glioblastoma 2025-11-22T17:21:02+00:00 hourly 0.9 https://trial.medpath.com/news/uskudar-university-partners-with-sartorius-to-advance-gene-therapy-and-cell-based-treatment-manufacturing-in-turkey 2025-11-22T17:20:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uskudar-university-partners-with-sartorius-to-advance-gene-therapy-and-cell-based-treatment-manufacturing-in-turkey 2025-11-22T17:20:53+00:00 hourly 0.9 https://trial.medpath.com/news/combicor-vax-phase-ii-trial-combines-dendritic-cell-vaccine-with-pembrolizumab-for-refractory-microsatellite-stable-metastatic-colorectal-cancer 2025-11-22T13:20:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/combicor-vax-phase-ii-trial-combines-dendritic-cell-vaccine-with-pembrolizumab-for-refractory-microsatellite-stable-metastatic-colorectal-cancer 2025-11-22T13:20:44+00:00 hourly 0.9 https://trial.medpath.com/news/osr-holdings-subsidiary-vaximm-secures-835m-licensing-deal-for-oral-cancer-immunotherapy-vxm01 2025-11-22T09:20:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/osr-holdings-subsidiary-vaximm-secures-835m-licensing-deal-for-oral-cancer-immunotherapy-vxm01 2025-11-22T09:20:52+00:00 hourly 0.9 https://trial.medpath.com/news/agc-biologics-partners-with-repair-biotechnologies-to-develop-novel-mrna-therapy-for-cardiovascular-disease 2025-11-22T05:21:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/agc-biologics-partners-with-repair-biotechnologies-to-develop-novel-mrna-therapy-for-cardiovascular-disease 2025-11-22T05:21:57+00:00 hourly 0.9 https://trial.medpath.com/news/real-world-study-reveals-treatment-gap-in-idh-mutant-glioma-supporting-need-for-early-intervention 2025-11-22T05:21:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/real-world-study-reveals-treatment-gap-in-idh-mutant-glioma-supporting-need-for-early-intervention 2025-11-22T05:21:20+00:00 hourly 0.9 https://trial.medpath.com/news/mirdametinib-achieves-87-response-rate-in-pediatric-low-grade-glioma-phase-1-2-trial 2025-11-22T05:21:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mirdametinib-achieves-87-response-rate-in-pediatric-low-grade-glioma-phase-1-2-trial 2025-11-22T05:21:15+00:00 hourly 0.9 https://trial.medpath.com/news/long-term-mirdametinib-data-shows-improved-response-rates-and-deeper-tumor-shrinkage-in-nf1-associated-plexiform-neurofibromas 2025-11-22T05:21:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/long-term-mirdametinib-data-shows-improved-response-rates-and-deeper-tumor-shrinkage-in-nf1-associated-plexiform-neurofibromas 2025-11-22T05:21:06+00:00 hourly 0.9 https://trial.medpath.com/news/immune-checkpoint-inhibitors-show-promise-for-triple-negative-breast-cancer-despite-increased-toxicity-risks 2025-11-22T05:21:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/immune-checkpoint-inhibitors-show-promise-for-triple-negative-breast-cancer-despite-increased-toxicity-risks 2025-11-22T05:21:04+00:00 hourly 0.9 https://trial.medpath.com/news/praxis-precision-medicines-advances-multiple-neurological-programs-following-essential-tremor-success 2025-11-22T05:20:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/praxis-precision-medicines-advances-multiple-neurological-programs-following-essential-tremor-success 2025-11-22T05:20:54+00:00 hourly 0.9 https://trial.medpath.com/news/aston-university-and-comvita-file-patent-for-enhanced-manuka-honey-formulation-against-drug-resistant-bacteria 2025-11-22T05:20:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aston-university-and-comvita-file-patent-for-enhanced-manuka-honey-formulation-against-drug-resistant-bacteria 2025-11-22T05:20:47+00:00 hourly 0.9 https://trial.medpath.com/news/uk-launches-first-clinical-trial-of-puberty-blockers-following-government-ban 2025-11-22T05:19:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uk-launches-first-clinical-trial-of-puberty-blockers-following-government-ban 2025-11-22T05:19:45+00:00 hourly 0.9 https://trial.medpath.com/news/revive-therapeutics-advances-bucillamine-research-for-nerve-agent-countermeasure-in-collaboration-with-canadian-defense-agency 2025-11-21T21:43:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/revive-therapeutics-advances-bucillamine-research-for-nerve-agent-countermeasure-in-collaboration-with-canadian-defense-agency 2025-11-21T21:43:28+00:00 hourly 0.9 https://trial.medpath.com/news/fda-investigates-fatal-adverse-event-linked-to-takeda-s-adzynma-enzyme-replacement-therapy 2025-11-21T21:40:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-investigates-fatal-adverse-event-linked-to-takeda-s-adzynma-enzyme-replacement-therapy 2025-11-21T21:40:10+00:00 hourly 0.9 https://trial.medpath.com/news/guselkumab-shows-superior-treatment-persistence-over-il-17a-inhibitors-in-psoriatic-arthritis-study 2025-11-21T21:37:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/guselkumab-shows-superior-treatment-persistence-over-il-17a-inhibitors-in-psoriatic-arthritis-study 2025-11-21T21:37:18+00:00 hourly 0.9 https://trial.medpath.com/news/astrazeneca-commits-2-billion-to-expand-maryland-manufacturing-operations-doubling-biologics-capacity 2025-11-21T21:36:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/astrazeneca-commits-2-billion-to-expand-maryland-manufacturing-operations-doubling-biologics-capacity 2025-11-21T21:36:01+00:00 hourly 0.9 https://trial.medpath.com/news/gsk-and-anaptysbio-file-dueling-lawsuits-over-jemperli-royalty-agreement-as-cancer-drug-nears-blockbuster-status 2025-11-21T21:31:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gsk-and-anaptysbio-file-dueling-lawsuits-over-jemperli-royalty-agreement-as-cancer-drug-nears-blockbuster-status 2025-11-21T21:31:42+00:00 hourly 0.9 https://trial.medpath.com/news/university-of-cincinnati-leads-multicenter-trial-testing-extended-tranexamic-acid-for-acl-surgery-recovery 2025-11-21T21:31:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/university-of-cincinnati-leads-multicenter-trial-testing-extended-tranexamic-acid-for-acl-surgery-recovery 2025-11-21T21:31:05+00:00 hourly 0.9 https://trial.medpath.com/news/u-s-cell-and-gene-therapy-cdmo-market-set-for-explosive-growth-projected-to-reach-10-34-billion-by-2033 2025-11-21T17:31:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/u-s-cell-and-gene-therapy-cdmo-market-set-for-explosive-growth-projected-to-reach-10-34-billion-by-2033 2025-11-21T17:31:36+00:00 hourly 0.9 https://trial.medpath.com/news/five-year-juliet-trial-data-confirms-tisagenlecleucel-as-curative-car-t-therapy-for-relapsed-refractory-large-b-cell-lymphoma 2025-11-21T17:25:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/five-year-juliet-trial-data-confirms-tisagenlecleucel-as-curative-car-t-therapy-for-relapsed-refractory-large-b-cell-lymphoma 2025-11-21T17:25:31+00:00 hourly 0.9 https://trial.medpath.com/news/polaryx-therapeutics-secures-nasdaq-listing-ahead-of-phase-2-trial-for-rare-lysosomal-storage-disorders 2025-11-21T17:23:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/polaryx-therapeutics-secures-nasdaq-listing-ahead-of-phase-2-trial-for-rare-lysosomal-storage-disorders 2025-11-21T17:23:13+00:00 hourly 0.9 https://trial.medpath.com/news/northwest-biotherapeutics-begins-construction-of-advanced-grade-c-manufacturing-suite-to-scale-dcvax-production 2025-11-21T17:22:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/northwest-biotherapeutics-begins-construction-of-advanced-grade-c-manufacturing-suite-to-scale-dcvax-production 2025-11-21T17:22:54+00:00 hourly 0.9 https://trial.medpath.com/news/sorcero-raises-42-5m-series-b-to-scale-ai-platform-for-life-sciences-evidence-generation 2025-11-21T17:22:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sorcero-raises-42-5m-series-b-to-scale-ai-platform-for-life-sciences-evidence-generation 2025-11-21T17:22:48+00:00 hourly 0.9 https://trial.medpath.com/news/fda-lifts-clinical-hold-on-blue-lake-s-pediatric-rsv-vaccine-trial-allowing-enrollment-of-rsv-negative-toddlers 2025-11-21T17:22:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-lifts-clinical-hold-on-blue-lake-s-pediatric-rsv-vaccine-trial-allowing-enrollment-of-rsv-negative-toddlers 2025-11-21T17:22:21+00:00 hourly 0.9 https://trial.medpath.com/news/nice-approves-alnylam-s-vutrisiran-for-nhs-use-in-rare-heart-condition-attr-cm 2025-11-21T17:22:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nice-approves-alnylam-s-vutrisiran-for-nhs-use-in-rare-heart-condition-attr-cm 2025-11-21T17:22:01+00:00 hourly 0.9 https://trial.medpath.com/news/waltz-health-launches-industry-first-direct-to-employer-model-for-obesity-medications 2025-11-21T17:21:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/waltz-health-launches-industry-first-direct-to-employer-model-for-obesity-medications 2025-11-21T17:21:17+00:00 hourly 0.9 https://trial.medpath.com/news/evofem-s-phexx-advances-toward-uae-approval-as-first-hormone-free-contraceptive-gel 2025-11-21T17:20:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/evofem-s-phexx-advances-toward-uae-approval-as-first-hormone-free-contraceptive-gel 2025-11-21T17:20:35+00:00 hourly 0.9 https://trial.medpath.com/news/contineum-therapeutics-pipe-307-fails-phase-2-multiple-sclerosis-trial 2025-11-21T13:59:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/contineum-therapeutics-pipe-307-fails-phase-2-multiple-sclerosis-trial 2025-11-21T13:59:04+00:00 hourly 0.9 https://trial.medpath.com/news/bioatla-secures-22-5-million-flexible-financing-to-support-operations-while-pursuing-strategic-partnership 2025-11-21T13:56:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bioatla-secures-22-5-million-flexible-financing-to-support-operations-while-pursuing-strategic-partnership 2025-11-21T13:56:12+00:00 hourly 0.9 https://trial.medpath.com/news/crossbridge-bio-secures-15-million-cprit-grant-to-advance-novel-dual-payload-adc-cbb-120-targeting-trop-2 2025-11-21T13:54:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/crossbridge-bio-secures-15-million-cprit-grant-to-advance-novel-dual-payload-adc-cbb-120-targeting-trop-2 2025-11-21T13:54:22+00:00 hourly 0.9 https://trial.medpath.com/news/meril-s-myval-transcatheter-heart-valve-shows-comparable-one-year-outcomes-to-leading-competitors-in-landmark-trial 2025-11-21T13:53:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/meril-s-myval-transcatheter-heart-valve-shows-comparable-one-year-outcomes-to-leading-competitors-in-landmark-trial 2025-11-21T13:53:58+00:00 hourly 0.9 https://trial.medpath.com/news/car-t-cell-therapy-shows-70-reduction-in-atherosclerotic-plaque-in-preclinical-study 2025-11-21T13:53:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/car-t-cell-therapy-shows-70-reduction-in-atherosclerotic-plaque-in-preclinical-study 2025-11-21T13:53:45+00:00 hourly 0.9 https://trial.medpath.com/news/dicot-pharma-s-lib-01-shows-sustained-erectile-dysfunction-treatment-effects-in-phase-2a-trial 2025-11-21T13:53:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dicot-pharma-s-lib-01-shows-sustained-erectile-dysfunction-treatment-effects-in-phase-2a-trial 2025-11-21T13:53:12+00:00 hourly 0.9 https://trial.medpath.com/news/cancer-cell-derived-il-1b-identified-as-key-mechanism-reversing-chemo-immunotherapy-resistance-in-nsclc 2025-11-21T13:52:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cancer-cell-derived-il-1b-identified-as-key-mechanism-reversing-chemo-immunotherapy-resistance-in-nsclc 2025-11-21T13:52:58+00:00 hourly 0.9 https://trial.medpath.com/news/gsk-subsidiary-tesaro-files-lawsuit-against-anaptysbio-over-jemperli-license-breach 2025-11-21T13:51:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gsk-subsidiary-tesaro-files-lawsuit-against-anaptysbio-over-jemperli-license-breach 2025-11-21T13:51:25+00:00 hourly 0.9 https://trial.medpath.com/news/curatis-secures-chf-1-2-million-to-accelerate-late-stage-corticorelin-development 2025-11-21T13:50:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/curatis-secures-chf-1-2-million-to-accelerate-late-stage-corticorelin-development 2025-11-21T13:50:36+00:00 hourly 0.9 https://trial.medpath.com/news/pacbio-gains-china-regulatory-approval-for-clinical-grade-long-read-sequencing-system 2025-11-21T13:50:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pacbio-gains-china-regulatory-approval-for-clinical-grade-long-read-sequencing-system 2025-11-21T13:50:30+00:00 hourly 0.9 https://trial.medpath.com/news/revir-therapeutics-secures-4-6m-cirm-grant-for-dual-target-huntington-s-disease-therapy 2025-11-21T09:57:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/revir-therapeutics-secures-4-6m-cirm-grant-for-dual-target-huntington-s-disease-therapy 2025-11-21T09:57:41+00:00 hourly 0.9 https://trial.medpath.com/news/onco-innovations-advances-pnkp-inhibitor-manufacturing-scale-up-with-dalton-pharma-for-phase-1-clinical-trials 2025-11-21T09:55:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/onco-innovations-advances-pnkp-inhibitor-manufacturing-scale-up-with-dalton-pharma-for-phase-1-clinical-trials 2025-11-21T09:55:34+00:00 hourly 0.9 https://trial.medpath.com/news/supreme-court-declines-patent-review-case-strengthening-ptab-authority-over-expired-patents 2025-11-21T01:27:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/supreme-court-declines-patent-review-case-strengthening-ptab-authority-over-expired-patents 2025-11-21T01:27:45+00:00 hourly 0.9 https://trial.medpath.com/news/actimed-therapeutics-partners-with-mankind-pharma-for-cancer-cachexia-treatment-development-in-south-asia 2025-11-21T01:24:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/actimed-therapeutics-partners-with-mankind-pharma-for-cancer-cachexia-treatment-development-in-south-asia 2025-11-21T01:24:57+00:00 hourly 0.9 https://trial.medpath.com/news/rare-pole-gene-mutation-predicts-strong-immunotherapy-response-in-colorectal-cancer 2025-11-21T01:24:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rare-pole-gene-mutation-predicts-strong-immunotherapy-response-in-colorectal-cancer 2025-11-21T01:24:47+00:00 hourly 0.9 https://trial.medpath.com/news/innocan-pharma-s-liposomal-cbd-platform-shows-28-day-sustained-release-in-preclinical-study 2025-11-21T01:23:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/innocan-pharma-s-liposomal-cbd-platform-shows-28-day-sustained-release-in-preclinical-study 2025-11-21T01:23:21+00:00 hourly 0.9 https://trial.medpath.com/news/os-therapies-plans-spinoff-of-animal-health-subsidiary-to-advance-canine-osteosarcoma-treatment 2025-11-21T01:23:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/os-therapies-plans-spinoff-of-animal-health-subsidiary-to-advance-canine-osteosarcoma-treatment 2025-11-21T01:23:12+00:00 hourly 0.9 https://trial.medpath.com/news/moderna-secures-1-5-billion-loan-to-advance-pipeline-beyond-covid-19-vaccines 2025-11-21T01:22:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/moderna-secures-1-5-billion-loan-to-advance-pipeline-beyond-covid-19-vaccines 2025-11-21T01:22:20+00:00 hourly 0.9 https://trial.medpath.com/news/inhibikase-therapeutics-advances-ikt-001-to-global-phase-3-study-for-pulmonary-arterial-hypertension 2025-11-21T01:21:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/inhibikase-therapeutics-advances-ikt-001-to-global-phase-3-study-for-pulmonary-arterial-hypertension 2025-11-21T01:21:20+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-multiple-new-cancer-therapies-including-bayer-s-hyrnuo-for-nsclc-and-amgen-s-imdelltra-for-small-cell-lung-cancer 2025-11-21T01:21:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-multiple-new-cancer-therapies-including-bayer-s-hyrnuo-for-nsclc-and-amgen-s-imdelltra-for-small-cell-lung-cancer 2025-11-21T01:21:07+00:00 hourly 0.9 https://trial.medpath.com/news/neurocrine-review-reveals-key-differences-between-fda-approved-tardive-dyskinesia-treatments 2025-11-21T01:21:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/neurocrine-review-reveals-key-differences-between-fda-approved-tardive-dyskinesia-treatments 2025-11-21T01:21:04+00:00 hourly 0.9 https://trial.medpath.com/news/aurigene-s-malt1-inhibitor-aur112-shows-63-6-response-rate-in-phase-1-lymphoma-trial 2025-11-21T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aurigene-s-malt1-inhibitor-aur112-shows-63-6-response-rate-in-phase-1-lymphoma-trial 2025-11-21T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/samsung-bioepis-explores-organon-acquisition-to-shift-from-partner-based-to-direct-sales-model 2025-11-20T22:32:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/samsung-bioepis-explores-organon-acquisition-to-shift-from-partner-based-to-direct-sales-model 2025-11-20T22:32:00+00:00 hourly 0.9 https://trial.medpath.com/news/european-medicines-agency-recommends-approval-for-two-boehringer-ingelheim-avian-flu-vaccines 2025-11-20T21:27:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/european-medicines-agency-recommends-approval-for-two-boehringer-ingelheim-avian-flu-vaccines 2025-11-20T21:27:13+00:00 hourly 0.9 https://trial.medpath.com/news/syncromune-s-sync-t-therapy-shows-bone-metastases-resolution-in-phase-1-prostate-cancer-trial 2025-11-20T21:27:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/syncromune-s-sync-t-therapy-shows-bone-metastases-resolution-in-phase-1-prostate-cancer-trial 2025-11-20T21:27:11+00:00 hourly 0.9 https://trial.medpath.com/news/mink-therapeutics-reports-preclinical-success-for-mink-215-car-inkt-therapy-in-treatment-resistant-solid-tumors 2025-11-20T21:26:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mink-therapeutics-reports-preclinical-success-for-mink-215-car-inkt-therapy-in-treatment-resistant-solid-tumors 2025-11-20T21:26:33+00:00 hourly 0.9 https://trial.medpath.com/news/fibrobiologics-secures-regulatory-approval-for-phase-1-2-trial-of-cywc628-in-diabetic-foot-ulcers 2025-11-20T21:24:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fibrobiologics-secures-regulatory-approval-for-phase-1-2-trial-of-cywc628-in-diabetic-foot-ulcers 2025-11-20T21:24:48+00:00 hourly 0.9 https://trial.medpath.com/news/polymodels-hub-raises-eur7-9m-series-a-to-transform-biopharma-process-development-with-ai-driven-platform 2025-11-20T21:22:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/polymodels-hub-raises-eur7-9m-series-a-to-transform-biopharma-process-development-with-ai-driven-platform 2025-11-20T21:22:33+00:00 hourly 0.9 https://trial.medpath.com/news/mauna-kea-technologies-secures-nmpa-approval-for-next-generation-cellvizio-platform-in-china 2025-11-20T21:22:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mauna-kea-technologies-secures-nmpa-approval-for-next-generation-cellvizio-platform-in-china 2025-11-20T21:22:22+00:00 hourly 0.9 https://trial.medpath.com/news/can-fite-s-cf602-receives-patent-protection-in-brazil-for-novel-erectile-dysfunction-treatment 2025-11-20T17:32:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/can-fite-s-cf602-receives-patent-protection-in-brazil-for-novel-erectile-dysfunction-treatment 2025-11-20T17:32:21+00:00 hourly 0.9 https://trial.medpath.com/news/pepromene-bio-s-baffr-car-t-therapy-shows-promising-results-in-relapsed-b-cell-cancers 2025-11-20T17:29:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pepromene-bio-s-baffr-car-t-therapy-shows-promising-results-in-relapsed-b-cell-cancers 2025-11-20T17:29:13+00:00 hourly 0.9 https://trial.medpath.com/news/vivac-pharma-appoints-keren-leshem-as-ceo-to-advance-rna-lipid-nanoparticle-cancer-immunotherapy-platform 2025-11-20T17:28:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vivac-pharma-appoints-keren-leshem-as-ceo-to-advance-rna-lipid-nanoparticle-cancer-immunotherapy-platform 2025-11-20T17:28:36+00:00 hourly 0.9 https://trial.medpath.com/news/minovia-s-mitochondrial-therapy-shows-promise-in-myelodysplastic-syndrome-phase-1b-trial 2025-11-20T17:25:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/minovia-s-mitochondrial-therapy-shows-promise-in-myelodysplastic-syndrome-phase-1b-trial 2025-11-20T17:25:22+00:00 hourly 0.9 https://trial.medpath.com/news/hitgen-secures-gates-foundation-funding-for-drug-discovery-targeting-tuberculosis-malaria-and-non-hormonal-contraception 2025-11-20T17:23:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hitgen-secures-gates-foundation-funding-for-drug-discovery-targeting-tuberculosis-malaria-and-non-hormonal-contraception 2025-11-20T17:23:41+00:00 hourly 0.9 https://trial.medpath.com/news/merck-kgaa-partners-with-valo-health-in-3-billion-ai-driven-parkinson-s-drug-discovery-deal 2025-11-20T17:23:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/merck-kgaa-partners-with-valo-health-in-3-billion-ai-driven-parkinson-s-drug-discovery-deal 2025-11-20T17:23:33+00:00 hourly 0.9 https://trial.medpath.com/news/qsimulate-raises-11m-in-seed-funding-launches-quelo-v2-3-quantum-platform-for-peptide-drug-discovery 2025-11-20T17:23:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/qsimulate-raises-11m-in-seed-funding-launches-quelo-v2-3-quantum-platform-for-peptide-drug-discovery 2025-11-20T17:23:30+00:00 hourly 0.9 https://trial.medpath.com/news/abbott-to-acquire-exact-sciences-for-21-billion-expanding-cancer-diagnostics-portfolio 2025-11-20T17:23:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/abbott-to-acquire-exact-sciences-for-21-billion-expanding-cancer-diagnostics-portfolio 2025-11-20T17:23:28+00:00 hourly 0.9 https://trial.medpath.com/news/briacell-partners-with-receptor-ai-to-develop-ai-driven-cancer-kinase-inhibitors 2025-11-20T17:22:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/briacell-partners-with-receptor-ai-to-develop-ai-driven-cancer-kinase-inhibitors 2025-11-20T17:22:51+00:00 hourly 0.9 https://trial.medpath.com/news/oncotelic-s-pipeline-receives-1-7-billion-valuation-as-ot-101-advances-to-phase-3-trials 2025-11-20T17:22:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oncotelic-s-pipeline-receives-1-7-billion-valuation-as-ot-101-advances-to-phase-3-trials 2025-11-20T17:22:09+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-accord-biopharma-s-denosumab-biosimilars-osvyrti-and-jubereq-for-bone-disorders 2025-11-20T17:22:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-accord-biopharma-s-denosumab-biosimilars-osvyrti-and-jubereq-for-bone-disorders 2025-11-20T17:22:06+00:00 hourly 0.9 https://trial.medpath.com/news/edgewise-therapeutics-strengthens-board-with-commercial-veteran-ahead-of-becker-muscular-dystrophy-launch 2025-11-20T17:22:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/edgewise-therapeutics-strengthens-board-with-commercial-veteran-ahead-of-becker-muscular-dystrophy-launch 2025-11-20T17:22:04+00:00 hourly 0.9 https://trial.medpath.com/news/unige-scientists-develop-dual-target-car-t-cell-therapy-for-treatment-resistant-glioblastoma 2025-11-20T17:21:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/unige-scientists-develop-dual-target-car-t-cell-therapy-for-treatment-resistant-glioblastoma 2025-11-20T17:21:01+00:00 hourly 0.9 https://trial.medpath.com/news/apoptotic-extracellular-vesicles-emerge-as-novel-biomarkers-for-cancer-and-neurodegenerative-disease-diagnosis 2025-11-20T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/apoptotic-extracellular-vesicles-emerge-as-novel-biomarkers-for-cancer-and-neurodegenerative-disease-diagnosis 2025-11-20T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/moderna-unveils-three-year-growth-strategy-with-expanded-vaccine-portfolio-and-oncology-focus 2025-11-20T13:27:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/moderna-unveils-three-year-growth-strategy-with-expanded-vaccine-portfolio-and-oncology-focus 2025-11-20T13:27:49+00:00 hourly 0.9 https://trial.medpath.com/news/novartis-raises-peak-sales-targets-for-cancer-drugs-kisqali-and-scemblix-forecasts-5-6-annual-growth-through-2030 2025-11-20T13:21:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novartis-raises-peak-sales-targets-for-cancer-drugs-kisqali-and-scemblix-forecasts-5-6-annual-growth-through-2030 2025-11-20T13:21:36+00:00 hourly 0.9 https://trial.medpath.com/news/imperial-college-spinout-biocentis-raises-19-million-to-advance-genome-engineered-insect-control-technology 2025-11-20T13:21:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/imperial-college-spinout-biocentis-raises-19-million-to-advance-genome-engineered-insect-control-technology 2025-11-20T13:21:28+00:00 hourly 0.9 https://trial.medpath.com/news/quantum-si-advances-proteus-platform-development-with-breakthrough-controlled-cleavage-chemistry-for-protein-sequencing 2025-11-20T13:21:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/quantum-si-advances-proteus-platform-development-with-breakthrough-controlled-cleavage-chemistry-for-protein-sequencing 2025-11-20T13:21:02+00:00 hourly 0.9 https://trial.medpath.com/news/ono-pharmaceutical-secures-approvals-for-braftovi-combination-therapy-in-braf-mutant-colorectal-cancer 2025-11-20T13:20:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ono-pharmaceutical-secures-approvals-for-braftovi-combination-therapy-in-braf-mutant-colorectal-cancer 2025-11-20T13:20:33+00:00 hourly 0.9 https://trial.medpath.com/news/flagship-pioneering-companies-enter-first-gsk-collaboration-agreements-to-target-respiratory-and-liver-diseases 2025-11-20T13:20:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/flagship-pioneering-companies-enter-first-gsk-collaboration-agreements-to-target-respiratory-and-liver-diseases 2025-11-20T13:20:13+00:00 hourly 0.9 https://trial.medpath.com/news/novartis-projects-5-6-annual-growth-through-2030-backed-by-multi-billion-dollar-drug-portfolio 2025-11-20T12:43:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novartis-projects-5-6-annual-growth-through-2030-backed-by-multi-billion-dollar-drug-portfolio 2025-11-20T12:43:00+00:00 hourly 0.9 https://trial.medpath.com/news/french-researchers-develop-novel-mrna-ultrasound-combination-therapy-for-pancreatic-cancer 2025-11-20T09:30:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/french-researchers-develop-novel-mrna-ultrasound-combination-therapy-for-pancreatic-cancer 2025-11-20T09:30:33+00:00 hourly 0.9 https://trial.medpath.com/news/poolbeg-pharma-secures-european-patent-for-polb-001-targeting-severe-influenza-and-cancer-immunotherapy-side-effects 2025-11-20T09:30:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/poolbeg-pharma-secures-european-patent-for-polb-001-targeting-severe-influenza-and-cancer-immunotherapy-side-effects 2025-11-20T09:30:30+00:00 hourly 0.9 https://trial.medpath.com/news/nhs-positioned-as-global-innovation-testbed-as-uk-attracts-40-billion-in-technology-investment 2025-11-20T09:14:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nhs-positioned-as-global-innovation-testbed-as-uk-attracts-40-billion-in-technology-investment 2025-11-20T09:14:21+00:00 hourly 0.9 https://trial.medpath.com/news/dexcom-launches-extended-15-day-g7-cgm-system-in-us-and-expands-g7-availability-in-kuwait 2025-11-20T08:29:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dexcom-launches-extended-15-day-g7-cgm-system-in-us-and-expands-g7-availability-in-kuwait 2025-11-20T08:29:00+00:00 hourly 0.9 https://trial.medpath.com/news/arch-biopartners-secures-600000-cad-to-advance-kidney-disease-drug-development 2025-11-20T05:21:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/arch-biopartners-secures-600000-cad-to-advance-kidney-disease-drug-development 2025-11-20T05:21:36+00:00 hourly 0.9 https://trial.medpath.com/news/impact-biotech-reports-73-complete-response-rate-in-phase-3-enlighted-trial-of-padeliporfin-vtp-for-low-grade-utuc 2025-11-20T05:21:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/impact-biotech-reports-73-complete-response-rate-in-phase-3-enlighted-trial-of-padeliporfin-vtp-for-low-grade-utuc 2025-11-20T05:21:27+00:00 hourly 0.9 https://trial.medpath.com/news/surenano-science-enters-letter-of-intent-to-acquire-glp-1-drug-developer-glucapharm 2025-11-20T01:24:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/surenano-science-enters-letter-of-intent-to-acquire-glp-1-drug-developer-glucapharm 2025-11-20T01:24:58+00:00 hourly 0.9 https://trial.medpath.com/news/checkmate-648-and-keynote-590-establish-chemo-immunotherapy-as-first-line-standard-for-advanced-esophageal-squamous-cell-carcinoma 2025-11-20T01:24:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/checkmate-648-and-keynote-590-establish-chemo-immunotherapy-as-first-line-standard-for-advanced-esophageal-squamous-cell-carcinoma 2025-11-20T01:24:20+00:00 hourly 0.9 https://trial.medpath.com/news/pfizer-s-mrna-flu-vaccine-shows-34-5-superior-efficacy-in-phase-3-trial 2025-11-20T01:24:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pfizer-s-mrna-flu-vaccine-shows-34-5-superior-efficacy-in-phase-3-trial 2025-11-20T01:24:08+00:00 hourly 0.9 https://trial.medpath.com/news/johns-hopkins-researchers-patent-enhanced-mebendazole-formulation-for-cancer-treatment 2025-11-20T01:21:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/johns-hopkins-researchers-patent-enhanced-mebendazole-formulation-for-cancer-treatment 2025-11-20T01:21:51+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-abbvie-and-genmab-s-epkinly-for-relapsed-or-refractory-follicular-lymphoma 2025-11-20T01:20:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-abbvie-and-genmab-s-epkinly-for-relapsed-or-refractory-follicular-lymphoma 2025-11-20T01:20:23+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-full-approval-to-amgen-s-imdelltra-for-extensive-stage-small-cell-lung-cancer 2025-11-20T01:20:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-full-approval-to-amgen-s-imdelltra-for-extensive-stage-small-cell-lung-cancer 2025-11-20T01:20:05+00:00 hourly 0.9 https://trial.medpath.com/news/ensysce-biosciences-advances-pf614-phase-3-trial-with-fda-manufacturing-approval-and-extended-patent-protection 2025-11-20T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ensysce-biosciences-advances-pf614-phase-3-trial-with-fda-manufacturing-approval-and-extended-patent-protection 2025-11-20T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/insphero-acquires-doppl-sa-and-sun-bioscience-gri3d-technology-to-create-comprehensive-3d-cell-model-platform 2025-11-20T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/insphero-acquires-doppl-sa-and-sun-bioscience-gri3d-technology-to-create-comprehensive-3d-cell-model-platform 2025-11-20T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/precise-bio-achieves-world-s-first-3d-bioprinted-corneal-implant-in-human-patient 2025-11-19T21:31:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/precise-bio-achieves-world-s-first-3d-bioprinted-corneal-implant-in-human-patient 2025-11-19T21:31:05+00:00 hourly 0.9 https://trial.medpath.com/news/dialectic-therapeutics-initiates-phase-1b-2-trial-of-dt2216-in-platinum-resistant-ovarian-cancer 2025-11-19T21:30:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dialectic-therapeutics-initiates-phase-1b-2-trial-of-dt2216-in-platinum-resistant-ovarian-cancer 2025-11-19T21:30:01+00:00 hourly 0.9 https://trial.medpath.com/news/avicanna-s-novel-pwdrx-platform-shows-74-higher-bioavailability-for-cannabinoid-delivery-in-preclinical-studies 2025-11-19T21:25:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/avicanna-s-novel-pwdrx-platform-shows-74-higher-bioavailability-for-cannabinoid-delivery-in-preclinical-studies 2025-11-19T21:25:36+00:00 hourly 0.9 https://trial.medpath.com/news/kaimrc-and-flagship-pioneering-form-70m-partnership-for-genetic-disease-clinical-trials-in-saudi-arabia 2025-11-19T21:25:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kaimrc-and-flagship-pioneering-form-70m-partnership-for-genetic-disease-clinical-trials-in-saudi-arabia 2025-11-19T21:25:02+00:00 hourly 0.9 https://trial.medpath.com/news/aperture-therapeutics-advances-cd33-targeting-antisense-oligonucleotide-aprtx-001-for-neurodegenerative-diseases 2025-11-19T21:24:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aperture-therapeutics-advances-cd33-targeting-antisense-oligonucleotide-aprtx-001-for-neurodegenerative-diseases 2025-11-19T21:24:05+00:00 hourly 0.9 https://trial.medpath.com/news/hrv-pharma-and-metrochem-form-strategic-cdmo-partnership-for-high-value-api-development 2025-11-19T21:20:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hrv-pharma-and-metrochem-form-strategic-cdmo-partnership-for-high-value-api-development 2025-11-19T21:20:57+00:00 hourly 0.9 https://trial.medpath.com/news/skin-permeable-polymer-delivers-insulin-through-topical-cream-offering-needle-free-diabetes-treatment 2025-11-19T21:20:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/skin-permeable-polymer-delivers-insulin-through-topical-cream-offering-needle-free-diabetes-treatment 2025-11-19T21:20:49+00:00 hourly 0.9 https://trial.medpath.com/news/abbott-laboratories-acquires-exact-sciences-for-21-billion-to-expand-cancer-diagnostics-portfolio 2025-11-19T19:21:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/abbott-laboratories-acquires-exact-sciences-for-21-billion-to-expand-cancer-diagnostics-portfolio 2025-11-19T19:21:00+00:00 hourly 0.9 https://trial.medpath.com/news/new-analysis-reveals-909-immunology-deals-worth-billions-in-biopharma-partnerships-from-2016-2025 2025-11-19T17:31:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/new-analysis-reveals-909-immunology-deals-worth-billions-in-biopharma-partnerships-from-2016-2025 2025-11-19T17:31:52+00:00 hourly 0.9 https://trial.medpath.com/news/scynexis-completes-brexafemme-nda-transfer-to-gsk-enabling-antifungal-drug-relaunch 2025-11-19T17:31:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/scynexis-completes-brexafemme-nda-transfer-to-gsk-enabling-antifungal-drug-relaunch 2025-11-19T17:31:42+00:00 hourly 0.9 https://trial.medpath.com/news/rxcelerate-and-constructive-bio-form-strategic-partnership-to-develop-next-generation-biologics-using-programmable-biology-platform 2025-11-19T17:30:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rxcelerate-and-constructive-bio-form-strategic-partnership-to-develop-next-generation-biologics-using-programmable-biology-platform 2025-11-19T17:30:38+00:00 hourly 0.9 https://trial.medpath.com/news/moderna-completes-140-million-u-s-manufacturing-expansion-to-enable-full-domestic-mrna-production 2025-11-19T17:30:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/moderna-completes-140-million-u-s-manufacturing-expansion-to-enable-full-domestic-mrna-production 2025-11-19T17:30:03+00:00 hourly 0.9 https://trial.medpath.com/news/agios-mitapivat-shows-mixed-results-in-phase-3-sickle-cell-disease-trial 2025-11-19T17:27:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/agios-mitapivat-shows-mixed-results-in-phase-3-sickle-cell-disease-trial 2025-11-19T17:27:43+00:00 hourly 0.9 https://trial.medpath.com/news/respirerx-secures-1-5m-nih-grant-to-advance-novel-epilepsy-treatment-krm-ii-81-toward-clinical-trials 2025-11-19T17:27:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/respirerx-secures-1-5m-nih-grant-to-advance-novel-epilepsy-treatment-krm-ii-81-toward-clinical-trials 2025-11-19T17:27:34+00:00 hourly 0.9 https://trial.medpath.com/news/novel-gene-therapy-avgn7-2-shows-promising-safety-profile-in-preclinical-study-for-inclusion-body-myositis 2025-11-19T17:27:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-gene-therapy-avgn7-2-shows-promising-safety-profile-in-preclinical-study-for-inclusion-body-myositis 2025-11-19T17:27:25+00:00 hourly 0.9 https://trial.medpath.com/news/distalmotion-secures-150m-series-g-to-expand-dexter-surgical-robot-in-u-s-ambulatory-surgery-centers 2025-11-19T17:26:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/distalmotion-secures-150m-series-g-to-expand-dexter-surgical-robot-in-u-s-ambulatory-surgery-centers 2025-11-19T17:26:54+00:00 hourly 0.9 https://trial.medpath.com/news/synthio-labs-raises-5-million-to-transform-life-sciences-customer-engagement-with-clinical-voice-ai 2025-11-19T17:26:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/synthio-labs-raises-5-million-to-transform-life-sciences-customer-engagement-with-clinical-voice-ai 2025-11-19T17:26:44+00:00 hourly 0.9 https://trial.medpath.com/news/c-light-technologies-wins-roche-ms-innovation-challenge-to-develop-eye-movement-biomarkers-for-multiple-sclerosis-progression 2025-11-19T17:25:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/c-light-technologies-wins-roche-ms-innovation-challenge-to-develop-eye-movement-biomarkers-for-multiple-sclerosis-progression 2025-11-19T17:25:53+00:00 hourly 0.9 https://trial.medpath.com/news/kalivir-partners-with-roche-to-test-novel-oncolytic-immunotherapy-vet3-tgi-in-combination-with-tecentriq 2025-11-19T17:25:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kalivir-partners-with-roche-to-test-novel-oncolytic-immunotherapy-vet3-tgi-in-combination-with-tecentriq 2025-11-19T17:25:50+00:00 hourly 0.9 https://trial.medpath.com/news/olema-pharmaceuticals-stock-falls-7-after-announcing-public-offering-to-fund-breast-cancer-pipeline 2025-11-19T17:25:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/olema-pharmaceuticals-stock-falls-7-after-announcing-public-offering-to-fund-breast-cancer-pipeline 2025-11-19T17:25:38+00:00 hourly 0.9 https://trial.medpath.com/news/tempest-therapeutics-acquires-dual-car-t-programs-from-factor-bioscience-in-strategic-all-stock-transaction 2025-11-19T17:25:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tempest-therapeutics-acquires-dual-car-t-programs-from-factor-bioscience-in-strategic-all-stock-transaction 2025-11-19T17:25:35+00:00 hourly 0.9 https://trial.medpath.com/news/elicio-therapeutics-appoints-marc-wolfgang-as-cto-to-strengthen-commercial-readiness-for-kras-targeted-cancer-immunotherapy 2025-11-19T17:25:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/elicio-therapeutics-appoints-marc-wolfgang-as-cto-to-strengthen-commercial-readiness-for-kras-targeted-cancer-immunotherapy 2025-11-19T17:25:07+00:00 hourly 0.9 https://trial.medpath.com/news/fyr-bio-and-nuvox-therapeutics-secure-1-98m-nci-grant-to-advance-liquid-biopsy-technology-in-glioblastoma-trial 2025-11-19T17:25:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fyr-bio-and-nuvox-therapeutics-secure-1-98m-nci-grant-to-advance-liquid-biopsy-technology-in-glioblastoma-trial 2025-11-19T17:25:01+00:00 hourly 0.9 https://trial.medpath.com/news/pfizer-partners-with-nona-biosciences-for-heavy-chain-only-antibody-discovery-platform 2025-11-19T17:24:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pfizer-partners-with-nona-biosciences-for-heavy-chain-only-antibody-discovery-platform 2025-11-19T17:24:59+00:00 hourly 0.9 https://trial.medpath.com/news/alzamend-neuro-completes-phase-ii-brain-imaging-study-of-novel-lithium-therapy-al001 2025-11-19T17:24:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alzamend-neuro-completes-phase-ii-brain-imaging-study-of-novel-lithium-therapy-al001 2025-11-19T17:24:56+00:00 hourly 0.9 https://trial.medpath.com/news/onepot-ai-emerges-from-stealth-with-13m-to-accelerate-drug-synthesis-using-ai-powered-chemistry 2025-11-19T17:24:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/onepot-ai-emerges-from-stealth-with-13m-to-accelerate-drug-synthesis-using-ai-powered-chemistry 2025-11-19T17:24:25+00:00 hourly 0.9 https://trial.medpath.com/news/india-launches-indigenous-crispr-gene-therapy-birsa-101-for-sickle-cell-disease-targeting-tribal-communities 2025-11-19T17:22:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/india-launches-indigenous-crispr-gene-therapy-birsa-101-for-sickle-cell-disease-targeting-tribal-communities 2025-11-19T17:22:19+00:00 hourly 0.9 https://trial.medpath.com/news/agios-mitapivat-shows-mixed-results-in-sickle-cell-disease-phase-3-trial 2025-11-19T17:21:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/agios-mitapivat-shows-mixed-results-in-sickle-cell-disease-phase-3-trial 2025-11-19T17:21:40+00:00 hourly 0.9 https://trial.medpath.com/news/tara-002-achieves-100-clinical-success-rate-in-phase-2-trial-for-pediatric-lymphatic-malformations 2025-11-19T17:21:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tara-002-achieves-100-clinical-success-rate-in-phase-2-trial-for-pediatric-lymphatic-malformations 2025-11-19T17:21:13+00:00 hourly 0.9 https://trial.medpath.com/news/dupilumab-demonstrates-superior-2-year-drug-survival-in-atopic-dermatitis-treatment-landscape 2025-11-19T15:06:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dupilumab-demonstrates-superior-2-year-drug-survival-in-atopic-dermatitis-treatment-landscape 2025-11-19T15:06:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-clears-dexcom-smart-basal-as-first-cgm-integrated-insulin-dosing-optimizer-for-type-2-diabetes 2025-11-19T13:31:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-clears-dexcom-smart-basal-as-first-cgm-integrated-insulin-dosing-optimizer-for-type-2-diabetes 2025-11-19T13:31:00+00:00 hourly 0.9 https://trial.medpath.com/news/profluent-secures-106m-to-advance-ai-driven-protein-design-platform 2025-11-19T13:24:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/profluent-secures-106m-to-advance-ai-driven-protein-design-platform 2025-11-19T13:24:02+00:00 hourly 0.9 https://trial.medpath.com/news/agc-biologics-partners-with-repair-biotechnologies-to-develop-novel-mrna-therapy-for-atherosclerotic-cardiovascular-disease 2025-11-19T13:23:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/agc-biologics-partners-with-repair-biotechnologies-to-develop-novel-mrna-therapy-for-atherosclerotic-cardiovascular-disease 2025-11-19T13:23:43+00:00 hourly 0.9 https://trial.medpath.com/news/piramal-pharma-solutions-uk-adc-manufacturing-facility-receives-updated-mhra-gmp-certification 2025-11-19T13:21:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/piramal-pharma-solutions-uk-adc-manufacturing-facility-receives-updated-mhra-gmp-certification 2025-11-19T13:21:34+00:00 hourly 0.9 https://trial.medpath.com/news/canon-medical-receives-fda-clearance-for-advanced-interventional-imaging-systems-with-ai-enhanced-technology 2025-11-19T13:12:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/canon-medical-receives-fda-clearance-for-advanced-interventional-imaging-systems-with-ai-enhanced-technology 2025-11-19T13:12:00+00:00 hourly 0.9 https://trial.medpath.com/news/gsk-partners-with-ltz-therapeutics-to-develop-novel-myeloid-cell-engagers-for-cancer-treatment 2025-11-19T09:22:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gsk-partners-with-ltz-therapeutics-to-develop-novel-myeloid-cell-engagers-for-cancer-treatment 2025-11-19T09:22:42+00:00 hourly 0.9 https://trial.medpath.com/news/breakthrough-in-remote-alzheimer-s-testing-finger-prick-blood-samples-enable-global-disease-detection 2025-11-19T09:22:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/breakthrough-in-remote-alzheimer-s-testing-finger-prick-blood-samples-enable-global-disease-detection 2025-11-19T09:22:39+00:00 hourly 0.9 https://trial.medpath.com/news/renalytix-s-kidneyintelx-dkd-test-shows-superior-ckd-risk-prediction-in-major-diabetes-care-study 2025-11-19T09:20:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/renalytix-s-kidneyintelx-dkd-test-shows-superior-ckd-risk-prediction-in-major-diabetes-care-study 2025-11-19T09:20:40+00:00 hourly 0.9 https://trial.medpath.com/news/first-patient-dosed-with-iv-psilocin-in-groundbreaking-binge-eating-disorder-trial 2025-11-19T09:20:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/first-patient-dosed-with-iv-psilocin-in-groundbreaking-binge-eating-disorder-trial 2025-11-19T09:20:34+00:00 hourly 0.9 https://trial.medpath.com/news/european-budget-impact-study-validates-economic-benefits-of-blue-light-cystoscopy-for-bladder-cancer-diagnosis 2025-11-19T07:34:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/european-budget-impact-study-validates-economic-benefits-of-blue-light-cystoscopy-for-bladder-cancer-diagnosis 2025-11-19T07:34:00+00:00 hourly 0.9 https://trial.medpath.com/news/yoltech-therapeutics-receives-fda-clearance-for-first-pivotal-trial-of-in-vivo-gene-editing-therapy-for-primary-hyperoxaluria-type-1 2025-11-19T05:22:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/yoltech-therapeutics-receives-fda-clearance-for-first-pivotal-trial-of-in-vivo-gene-editing-therapy-for-primary-hyperoxaluria-type-1 2025-11-19T05:22:24+00:00 hourly 0.9 https://trial.medpath.com/news/cognito-therapeutics-spectris-device-shows-promise-in-modulating-brain-resilience-pathways-in-alzheimer-s-disease 2025-11-19T05:21:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cognito-therapeutics-spectris-device-shows-promise-in-modulating-brain-resilience-pathways-in-alzheimer-s-disease 2025-11-19T05:21:22+00:00 hourly 0.9 https://trial.medpath.com/news/brain-biomarkers-predict-deep-brain-stimulation-success-in-treatment-resistant-depression 2025-11-19T05:21:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/brain-biomarkers-predict-deep-brain-stimulation-success-in-treatment-resistant-depression 2025-11-19T05:21:16+00:00 hourly 0.9 https://trial.medpath.com/news/lynk-pharmaceuticals-topical-jak-inhibitor-lnk01004-shows-promising-phase-ii-results-for-moderate-to-severe-atopic-dermatitis 2025-11-19T05:20:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lynk-pharmaceuticals-topical-jak-inhibitor-lnk01004-shows-promising-phase-ii-results-for-moderate-to-severe-atopic-dermatitis 2025-11-19T05:20:13+00:00 hourly 0.9 https://trial.medpath.com/news/familywell-health-secures-8m-series-a-to-expand-integrated-women-s-mental-health-platform 2025-11-19T01:30:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/familywell-health-secures-8m-series-a-to-expand-integrated-women-s-mental-health-platform 2025-11-19T01:30:36+00:00 hourly 0.9 https://trial.medpath.com/news/vincere-biosciences-secures-5-million-mjff-grant-to-advance-first-in-class-parkinson-s-usp30-inhibitor-to-clinical-trials 2025-11-19T01:29:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vincere-biosciences-secures-5-million-mjff-grant-to-advance-first-in-class-parkinson-s-usp30-inhibitor-to-clinical-trials 2025-11-19T01:29:52+00:00 hourly 0.9 https://trial.medpath.com/news/vast-therapeutics-alx1-shows-promising-safety-profile-in-phase-1-trial-for-chronic-respiratory-diseases 2025-11-19T01:27:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vast-therapeutics-alx1-shows-promising-safety-profile-in-phase-1-trial-for-chronic-respiratory-diseases 2025-11-19T01:27:11+00:00 hourly 0.9 https://trial.medpath.com/news/nervgen-pharma-secures-10-million-funding-to-advance-first-in-class-spinal-cord-injury-therapy-nvg-291 2025-11-19T01:27:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nervgen-pharma-secures-10-million-funding-to-advance-first-in-class-spinal-cord-injury-therapy-nvg-291 2025-11-19T01:27:00+00:00 hourly 0.9 https://trial.medpath.com/news/truth-dkd-trial-compares-tofogliflozin-and-metformin-for-diabetic-kidney-disease-treatment 2025-11-19T01:26:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/truth-dkd-trial-compares-tofogliflozin-and-metformin-for-diabetic-kidney-disease-treatment 2025-11-19T01:26:48+00:00 hourly 0.9 https://trial.medpath.com/news/biocytics-achieves-fda-interact-meeting-milestone-for-point-of-care-cell-therapy-platform 2025-11-19T01:26:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biocytics-achieves-fda-interact-meeting-milestone-for-point-of-care-cell-therapy-platform 2025-11-19T01:26:21+00:00 hourly 0.9 https://trial.medpath.com/news/onco-innovations-partners-with-kuano-to-apply-quantum-computing-to-pnkp-inhibitor-development 2025-11-19T01:25:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/onco-innovations-partners-with-kuano-to-apply-quantum-computing-to-pnkp-inhibitor-development 2025-11-19T01:25:14+00:00 hourly 0.9 https://trial.medpath.com/news/nature-cell-to-establish-4m-stem-cell-manufacturing-facility-in-baltimore-creating-500-jobs 2025-11-19T01:24:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nature-cell-to-establish-4m-stem-cell-manufacturing-facility-in-baltimore-creating-500-jobs 2025-11-19T01:24:26+00:00 hourly 0.9 https://trial.medpath.com/news/three-year-izervay-data-shows-sustained-reduction-in-geographic-atrophy-lesion-growth 2025-11-19T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/three-year-izervay-data-shows-sustained-reduction-in-geographic-atrophy-lesion-growth 2025-11-19T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/alector-s-late-stage-frontotemporal-dementia-drug-fails-phase-iii-trial-company-cuts-workforce-by-49 2025-11-18T21:27:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alector-s-late-stage-frontotemporal-dementia-drug-fails-phase-iii-trial-company-cuts-workforce-by-49 2025-11-18T21:27:06+00:00 hourly 0.9 https://trial.medpath.com/news/federal-circuit-invalidates-39-million-hair-loss-drug-patent-in-sandoz-victory 2025-11-18T21:26:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/federal-circuit-invalidates-39-million-hair-loss-drug-patent-in-sandoz-victory 2025-11-18T21:26:31+00:00 hourly 0.9 https://trial.medpath.com/news/invenirex-secures-ps2m-to-commercialize-revolutionary-dna-nanotechnology-platform-for-ultra-early-disease-detection 2025-11-18T21:25:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/invenirex-secures-ps2m-to-commercialize-revolutionary-dna-nanotechnology-platform-for-ultra-early-disease-detection 2025-11-18T21:25:16+00:00 hourly 0.9 https://trial.medpath.com/news/eve-bio-and-drugbank-partner-to-integrate-record-scale-pharmome-mapping-data-into-drug-discovery-platform 2025-11-18T21:24:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eve-bio-and-drugbank-partner-to-integrate-record-scale-pharmome-mapping-data-into-drug-discovery-platform 2025-11-18T21:24:07+00:00 hourly 0.9 https://trial.medpath.com/news/metformin-fails-to-delay-progression-in-low-risk-prostate-cancer-active-surveillance 2025-11-18T21:23:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/metformin-fails-to-delay-progression-in-low-risk-prostate-cancer-active-surveillance 2025-11-18T21:23:49+00:00 hourly 0.9 https://trial.medpath.com/news/arrowhead-pharmaceuticals-secures-first-fda-approval-with-redemplo-for-rare-genetic-disorder 2025-11-18T21:20:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/arrowhead-pharmaceuticals-secures-first-fda-approval-with-redemplo-for-rare-genetic-disorder 2025-11-18T21:20:23+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-first-sirna-therapy-plozasiran-for-rare-metabolic-disorder-familial-chylomicronemia-syndrome 2025-11-18T21:20:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-first-sirna-therapy-plozasiran-for-rare-metabolic-disorder-familial-chylomicronemia-syndrome 2025-11-18T21:20:20+00:00 hourly 0.9 https://trial.medpath.com/news/nice-approves-talquetamab-for-nhs-use-offering-new-hope-for-multiple-myeloma-patients 2025-11-18T21:20:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nice-approves-talquetamab-for-nhs-use-offering-new-hope-for-multiple-myeloma-patients 2025-11-18T21:20:18+00:00 hourly 0.9 https://trial.medpath.com/news/oxford-and-gsk-launch-ps50-million-partnership-to-advance-cancer-prevention-and-inflammatory-disease-research 2025-11-18T21:19:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oxford-and-gsk-launch-ps50-million-partnership-to-advance-cancer-prevention-and-inflammatory-disease-research 2025-11-18T21:19:43+00:00 hourly 0.9 https://trial.medpath.com/news/regeneron-seeks-to-strike-amgen-s-patent-counterclaims-in-aflibercept-biosimilar-litigation 2025-11-18T19:55:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/regeneron-seeks-to-strike-amgen-s-patent-counterclaims-in-aflibercept-biosimilar-litigation 2025-11-18T19:55:00+00:00 hourly 0.9 https://trial.medpath.com/news/arcera-life-sciences-launches-breakthrough-antibiotic-in-uae-to-combat-antimicrobial-resistance 2025-11-18T18:23:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/arcera-life-sciences-launches-breakthrough-antibiotic-in-uae-to-combat-antimicrobial-resistance 2025-11-18T18:23:00+00:00 hourly 0.9 https://trial.medpath.com/news/health-canada-approves-nilemdo-for-ldl-cholesterol-reduction-in-cardiovascular-disease-patients 2025-11-18T17:36:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/health-canada-approves-nilemdo-for-ldl-cholesterol-reduction-in-cardiovascular-disease-patients 2025-11-18T17:36:15+00:00 hourly 0.9 https://trial.medpath.com/news/vyome-holdings-reports-positive-phase-2-results-for-vt-1953-in-malignant-fungating-wounds 2025-11-18T17:35:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vyome-holdings-reports-positive-phase-2-results-for-vt-1953-in-malignant-fungating-wounds 2025-11-18T17:35:05+00:00 hourly 0.9 https://trial.medpath.com/news/clairity-secures-43m-series-b-to-commercialize-first-fda-authorized-ai-platform-for-breast-cancer-risk-prediction 2025-11-18T17:35:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/clairity-secures-43m-series-b-to-commercialize-first-fda-authorized-ai-platform-for-breast-cancer-risk-prediction 2025-11-18T17:35:02+00:00 hourly 0.9 https://trial.medpath.com/news/inmed-s-alzheimer-s-drug-candidate-inm-901-shows-favorable-bioavailability-in-large-animal-studies 2025-11-18T17:33:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/inmed-s-alzheimer-s-drug-candidate-inm-901-shows-favorable-bioavailability-in-large-animal-studies 2025-11-18T17:33:41+00:00 hourly 0.9 https://trial.medpath.com/news/singapore-researchers-develop-rna-therapy-targeting-undruggable-kras-cancer-gene 2025-11-18T17:33:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/singapore-researchers-develop-rna-therapy-targeting-undruggable-kras-cancer-gene 2025-11-18T17:33:35+00:00 hourly 0.9 https://trial.medpath.com/news/thermo-fisher-scientific-opens-east-coast-advanced-therapies-collaboration-center-to-accelerate-cell-and-gene-therapy-development 2025-11-18T17:32:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/thermo-fisher-scientific-opens-east-coast-advanced-therapies-collaboration-center-to-accelerate-cell-and-gene-therapy-development 2025-11-18T17:32:56+00:00 hourly 0.9 https://trial.medpath.com/news/hermes-biosciences-secures-seed-funding-to-advance-extracellular-vesicle-isolation-technology-for-precision-medicine 2025-11-18T17:32:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hermes-biosciences-secures-seed-funding-to-advance-extracellular-vesicle-isolation-technology-for-precision-medicine 2025-11-18T17:32:18+00:00 hourly 0.9 https://trial.medpath.com/news/zymeworks-pivots-to-royalty-driven-model-following-ziihera-s-late-stage-success-in-gastroesophageal-cancer 2025-11-18T17:31:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/zymeworks-pivots-to-royalty-driven-model-following-ziihera-s-late-stage-success-in-gastroesophageal-cancer 2025-11-18T17:31:32+00:00 hourly 0.9 https://trial.medpath.com/news/brazilian-researchers-identify-amazon-scorpion-venom-peptide-with-promising-anti-breast-cancer-activity 2025-11-18T17:29:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/brazilian-researchers-identify-amazon-scorpion-venom-peptide-with-promising-anti-breast-cancer-activity 2025-11-18T17:29:52+00:00 hourly 0.9 https://trial.medpath.com/news/radiopharm-theranostics-receives-ethics-approval-for-first-in-human-trial-of-rad-402-in-advanced-prostate-cancer 2025-11-18T17:29:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/radiopharm-theranostics-receives-ethics-approval-for-first-in-human-trial-of-rad-402-in-advanced-prostate-cancer 2025-11-18T17:29:47+00:00 hourly 0.9 https://trial.medpath.com/news/mabloc-and-instituto-butantan-partner-to-develop-first-in-class-monoclonal-antibody-therapy-for-yellow-fever 2025-11-18T17:29:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mabloc-and-instituto-butantan-partner-to-develop-first-in-class-monoclonal-antibody-therapy-for-yellow-fever 2025-11-18T17:29:44+00:00 hourly 0.9 https://trial.medpath.com/news/federal-circuit-upholds-patent-invalidation-of-merck-s-oral-cladribine-ms-treatment-regimen 2025-11-18T17:28:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/federal-circuit-upholds-patent-invalidation-of-merck-s-oral-cladribine-ms-treatment-regimen 2025-11-18T17:28:45+00:00 hourly 0.9 https://trial.medpath.com/news/hcw-biologics-initiates-first-in-human-trial-of-il-2-fusion-therapy-hcw9302-for-alopecia-areata 2025-11-18T17:28:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hcw-biologics-initiates-first-in-human-trial-of-il-2-fusion-therapy-hcw9302-for-alopecia-areata 2025-11-18T17:28:17+00:00 hourly 0.9 https://trial.medpath.com/news/quanterix-validates-dual-blood-biomarker-test-for-comprehensive-multiple-sclerosis-monitoring 2025-11-18T17:27:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/quanterix-validates-dual-blood-biomarker-test-for-comprehensive-multiple-sclerosis-monitoring 2025-11-18T17:27:58+00:00 hourly 0.9 https://trial.medpath.com/news/csl-announces-1-5-billion-u-s-investment-to-expand-plasma-derived-therapy-manufacturing 2025-11-18T17:27:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/csl-announces-1-5-billion-u-s-investment-to-expand-plasma-derived-therapy-manufacturing 2025-11-18T17:27:32+00:00 hourly 0.9 https://trial.medpath.com/news/hepatitis-c-pricing-wars-of-2014-offer-blueprint-for-current-glp-1-obesity-drug-competition 2025-11-18T17:27:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hepatitis-c-pricing-wars-of-2014-offer-blueprint-for-current-glp-1-obesity-drug-competition 2025-11-18T17:27:17+00:00 hourly 0.9 https://trial.medpath.com/news/tivic-health-secures-barda-meeting-to-advance-entolimod-for-acute-radiation-syndrome 2025-11-18T17:25:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tivic-health-secures-barda-meeting-to-advance-entolimod-for-acute-radiation-syndrome 2025-11-18T17:25:13+00:00 hourly 0.9 https://trial.medpath.com/news/kangpu-s-novel-cereblon-modulator-shows-50-response-rate-in-heavily-pre-treated-multiple-myeloma-patients 2025-11-18T17:25:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kangpu-s-novel-cereblon-modulator-shows-50-response-rate-in-heavily-pre-treated-multiple-myeloma-patients 2025-11-18T17:25:07+00:00 hourly 0.9 https://trial.medpath.com/news/vanda-s-tradipitant-reduces-glp-1-induced-vomiting-by-50-in-phase-2-trial 2025-11-18T17:24:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vanda-s-tradipitant-reduces-glp-1-induced-vomiting-by-50-in-phase-2-trial 2025-11-18T17:24:12+00:00 hourly 0.9 https://trial.medpath.com/news/can-fite-reports-9-year-complete-response-in-advanced-liver-cancer-patient-as-phase-iii-trial-enrolls 2025-11-18T17:23:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/can-fite-reports-9-year-complete-response-in-advanced-liver-cancer-patient-as-phase-iii-trial-enrolls 2025-11-18T17:23:54+00:00 hourly 0.9 https://trial.medpath.com/news/bionet-s-vacpertagen-receives-positive-ema-opinion-as-first-standalone-pertussis-vaccine-in-eu 2025-11-18T17:23:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bionet-s-vacpertagen-receives-positive-ema-opinion-as-first-standalone-pertussis-vaccine-in-eu 2025-11-18T17:23:12+00:00 hourly 0.9 https://trial.medpath.com/news/uk-launches-ps18-8-million-initiative-to-transform-nuclear-waste-into-precision-cancer-therapies 2025-11-18T17:23:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uk-launches-ps18-8-million-initiative-to-transform-nuclear-waste-into-precision-cancer-therapies 2025-11-18T17:23:07+00:00 hourly 0.9 https://trial.medpath.com/news/nanopath-receives-fda-breakthrough-device-designation-for-point-of-care-molecular-uti-diagnostic-platform 2025-11-18T17:22:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nanopath-receives-fda-breakthrough-device-designation-for-point-of-care-molecular-uti-diagnostic-platform 2025-11-18T17:22:23+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-first-antithrombin-concentrate-for-pediatric-patients-with-hereditary-antithrombin-deficiency 2025-11-18T17:22:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-first-antithrombin-concentrate-for-pediatric-patients-with-hereditary-antithrombin-deficiency 2025-11-18T17:22:21+00:00 hourly 0.9 https://trial.medpath.com/news/cryotherapeutics-launches-icecap-trial-combining-cryotherapy-with-ai-powered-imaging-to-target-high-risk-coronary-plaques 2025-11-18T17:22:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cryotherapeutics-launches-icecap-trial-combining-cryotherapy-with-ai-powered-imaging-to-target-high-risk-coronary-plaques 2025-11-18T17:22:00+00:00 hourly 0.9 https://trial.medpath.com/news/advocate-health-launches-nation-s-largest-clinical-trial-network-to-democratize-access-to-breakthrough-treatments 2025-11-18T17:21:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/advocate-health-launches-nation-s-largest-clinical-trial-network-to-democratize-access-to-breakthrough-treatments 2025-11-18T17:21:02+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-first-bispecific-antibody-combination-for-relapsed-refractory-follicular-lymphoma 2025-11-18T17:20:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-first-bispecific-antibody-combination-for-relapsed-refractory-follicular-lymphoma 2025-11-18T17:20:31+00:00 hourly 0.9 https://trial.medpath.com/news/mro-acquires-ai-driven-clinical-trial-recruitment-platform-clinetic-to-streamline-patient-enrollment 2025-11-18T17:20:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mro-acquires-ai-driven-clinical-trial-recruitment-platform-clinetic-to-streamline-patient-enrollment 2025-11-18T17:20:28+00:00 hourly 0.9 https://trial.medpath.com/news/cellbyte-secures-2-75m-to-accelerate-drug-launch-timelines-with-ai-platform 2025-11-18T17:20:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cellbyte-secures-2-75m-to-accelerate-drug-launch-timelines-with-ai-platform 2025-11-18T17:20:01+00:00 hourly 0.9 https://trial.medpath.com/news/dual-pd-1-ctla-4-immunotherapy-shows-promise-in-ovarian-cancer-treatment 2025-11-18T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dual-pd-1-ctla-4-immunotherapy-shows-promise-in-ovarian-cancer-treatment 2025-11-18T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/multiple-sclerosis-patients-show-preserved-covid-19-vaccine-responses-despite-disease-modifying-therapies 2025-11-18T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/multiple-sclerosis-patients-show-preserved-covid-19-vaccine-responses-despite-disease-modifying-therapies 2025-11-18T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/health-canada-opens-consultation-on-decentralized-clinical-trials-guidance-as-global-regulatory-frameworks-converge 2025-11-18T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/health-canada-opens-consultation-on-decentralized-clinical-trials-guidance-as-global-regulatory-frameworks-converge 2025-11-18T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/european-commission-approves-world-s-first-liquid-formulation-of-iv-infliximab-promising-significant-cost-savings 2025-11-18T13:25:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/european-commission-approves-world-s-first-liquid-formulation-of-iv-infliximab-promising-significant-cost-savings 2025-11-18T13:25:28+00:00 hourly 0.9 https://trial.medpath.com/news/emulate-and-fujifilm-launch-brain-chip-r1-to-overcome-blood-brain-barrier-challenges-in-cns-drug-development 2025-11-18T13:22:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/emulate-and-fujifilm-launch-brain-chip-r1-to-overcome-blood-brain-barrier-challenges-in-cns-drug-development 2025-11-18T13:22:04+00:00 hourly 0.9 https://trial.medpath.com/news/avanzanite-secures-eur32m-series-a-to-scale-rare-disease-drug-access-across-europe 2025-11-18T13:20:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/avanzanite-secures-eur32m-series-a-to-scale-rare-disease-drug-access-across-europe 2025-11-18T13:20:50+00:00 hourly 0.9 https://trial.medpath.com/news/medicinova-strengthens-leadership-with-fda-veteran-dr-christopher-breder-as-clinical-and-regulatory-advisor 2025-11-18T13:20:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/medicinova-strengthens-leadership-with-fda-veteran-dr-christopher-breder-as-clinical-and-regulatory-advisor 2025-11-18T13:20:21+00:00 hourly 0.9 https://trial.medpath.com/news/koru-medical-submits-fda-510-k-application-for-freedomedge-infusion-system-with-oncology-biologic-phesgo 2025-11-18T11:37:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/koru-medical-submits-fda-510-k-application-for-freedomedge-infusion-system-with-oncology-biologic-phesgo 2025-11-18T11:37:00+00:00 hourly 0.9 https://trial.medpath.com/news/federal-circuit-overturns-39-million-jury-verdict-invalidates-allergan-hair-loss-patent-for-inadequate-written-description 2025-11-18T10:15:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/federal-circuit-overturns-39-million-jury-verdict-invalidates-allergan-hair-loss-patent-for-inadequate-written-description 2025-11-18T10:15:00+00:00 hourly 0.9 https://trial.medpath.com/news/ubivac-s-dpv-001-cancer-vaccine-shows-3x-response-rate-improvement-in-head-and-neck-cancer-trial 2025-11-18T09:21:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ubivac-s-dpv-001-cancer-vaccine-shows-3x-response-rate-improvement-in-head-and-neck-cancer-trial 2025-11-18T09:21:49+00:00 hourly 0.9 https://trial.medpath.com/news/gsk-and-fleming-initiative-launch-ps45m-ai-powered-research-program-to-combat-antimicrobial-resistance 2025-11-18T09:21:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gsk-and-fleming-initiative-launch-ps45m-ai-powered-research-program-to-combat-antimicrobial-resistance 2025-11-18T09:21:22+00:00 hourly 0.9 https://trial.medpath.com/news/biomx-secures-3-0-million-private-placement-to-advance-bacteriophage-therapies-for-bacterial-infections 2025-11-18T08:30:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biomx-secures-3-0-million-private-placement-to-advance-bacteriophage-therapies-for-bacterial-infections 2025-11-18T08:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/mainz-biomed-achieves-100-sensitivity-in-pancreatic-cancer-blood-test-feasibility-study 2025-11-18T08:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mainz-biomed-achieves-100-sensitivity-in-pancreatic-cancer-blood-test-feasibility-study 2025-11-18T08:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/sonoma-biotherapeutics-appoints-new-ceo-following-positive-treg-therapy-trial-results 2025-11-18T05:23:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sonoma-biotherapeutics-appoints-new-ceo-following-positive-treg-therapy-trial-results 2025-11-18T05:23:55+00:00 hourly 0.9 https://trial.medpath.com/news/high-immune-infiltration-predicts-worse-outcomes-in-bevacizumab-treated-ovarian-cancer-patients 2025-11-18T05:21:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/high-immune-infiltration-predicts-worse-outcomes-in-bevacizumab-treated-ovarian-cancer-patients 2025-11-18T05:21:16+00:00 hourly 0.9 https://trial.medpath.com/news/genesis-medtech-and-national-university-health-system-launch-four-year-ai-partnership-to-transform-surgical-care 2025-11-18T05:20:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/genesis-medtech-and-national-university-health-system-launch-four-year-ai-partnership-to-transform-surgical-care 2025-11-18T05:20:12+00:00 hourly 0.9 https://trial.medpath.com/news/70-year-old-blood-pressure-drug-hydralazine-shows-promise-against-aggressive-brain-tumors 2025-11-18T05:19:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/70-year-old-blood-pressure-drug-hydralazine-shows-promise-against-aggressive-brain-tumors 2025-11-18T05:19:57+00:00 hourly 0.9 https://trial.medpath.com/news/microdose-cannabis-extract-shows-promise-in-slowing-cognitive-decline-in-alzheimer-s-patients 2025-11-18T03:47:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/microdose-cannabis-extract-shows-promise-in-slowing-cognitive-decline-in-alzheimer-s-patients 2025-11-18T03:47:00+00:00 hourly 0.9 https://trial.medpath.com/news/art-501-shows-promise-in-phase-2a-trial-for-autism-spectrum-disorder-treatment 2025-11-18T01:24:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/art-501-shows-promise-in-phase-2a-trial-for-autism-spectrum-disorder-treatment 2025-11-18T01:24:05+00:00 hourly 0.9 https://trial.medpath.com/news/johnson-johnson-acquires-halda-therapeutics-for-3-05-billion-to-strengthen-oncology-pipeline 2025-11-18T01:23:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/johnson-johnson-acquires-halda-therapeutics-for-3-05-billion-to-strengthen-oncology-pipeline 2025-11-18T01:23:33+00:00 hourly 0.9 https://trial.medpath.com/news/cincinnati-children-s-opens-expanded-gene-and-cell-therapy-manufacturing-center-to-accelerate-clinical-trials 2025-11-18T01:21:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cincinnati-children-s-opens-expanded-gene-and-cell-therapy-manufacturing-center-to-accelerate-clinical-trials 2025-11-18T01:21:58+00:00 hourly 0.9 https://trial.medpath.com/news/terray-therapeutics-achieves-drug-discovery-milestone-with-bristol-myers-squibb-using-ai-native-emmi-platform 2025-11-18T01:21:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/terray-therapeutics-achieves-drug-discovery-milestone-with-bristol-myers-squibb-using-ai-native-emmi-platform 2025-11-18T01:21:17+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-komzifti-as-first-once-daily-oral-menin-inhibitor-for-relapsed-npm1-mutated-aml 2025-11-18T01:20:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-komzifti-as-first-once-daily-oral-menin-inhibitor-for-relapsed-npm1-mutated-aml 2025-11-18T01:20:46+00:00 hourly 0.9 https://trial.medpath.com/news/federal-judge-approves-purdue-pharma-s-7-4-billion-opioid-settlement 2025-11-18T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/federal-judge-approves-purdue-pharma-s-7-4-billion-opioid-settlement 2025-11-18T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/aclipse-therapeutics-partners-with-mayo-clinic-for-phase-2-trial-of-first-disease-modifying-gastroparesis-treatment 2025-11-17T21:33:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aclipse-therapeutics-partners-with-mayo-clinic-for-phase-2-trial-of-first-disease-modifying-gastroparesis-treatment 2025-11-17T21:33:04+00:00 hourly 0.9 https://trial.medpath.com/news/dry-amd-market-set-for-significant-growth-through-2034-as-novel-therapies-advance-in-clinical-development 2025-11-17T21:32:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dry-amd-market-set-for-significant-growth-through-2034-as-novel-therapies-advance-in-clinical-development 2025-11-17T21:32:29+00:00 hourly 0.9 https://trial.medpath.com/news/scynexis-secures-35-million-nih-grant-to-advance-next-generation-antifungal-therapeutics 2025-11-17T21:32:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/scynexis-secures-35-million-nih-grant-to-advance-next-generation-antifungal-therapeutics 2025-11-17T21:32:24+00:00 hourly 0.9 https://trial.medpath.com/news/protara-therapeutics-to-present-phase-2-tara-002-data-for-bcg-naive-bladder-cancer-patients-at-suo-meeting 2025-11-17T21:31:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/protara-therapeutics-to-present-phase-2-tara-002-data-for-bcg-naive-bladder-cancer-patients-at-suo-meeting 2025-11-17T21:31:36+00:00 hourly 0.9 https://trial.medpath.com/news/azurity-pharmaceuticals-acquires-sebela-s-bowel-prep-franchise-as-sebela-advances-gerd-drug-tegoprazan-to-fda-submission 2025-11-17T21:30:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/azurity-pharmaceuticals-acquires-sebela-s-bowel-prep-franchise-as-sebela-advances-gerd-drug-tegoprazan-to-fda-submission 2025-11-17T21:30:27+00:00 hourly 0.9 https://trial.medpath.com/news/raphael-pharmaceutical-files-patent-for-thc-free-cannabinoid-therapy-targeting-rheumatoid-arthritis 2025-11-17T21:28:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/raphael-pharmaceutical-files-patent-for-thc-free-cannabinoid-therapy-targeting-rheumatoid-arthritis 2025-11-17T21:28:59+00:00 hourly 0.9 https://trial.medpath.com/news/delhi-high-court-allows-natco-pharma-to-continue-cyantraniliprole-insecticide-sales-despite-fmc-patent-dispute 2025-11-17T21:28:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/delhi-high-court-allows-natco-pharma-to-continue-cyantraniliprole-insecticide-sales-despite-fmc-patent-dispute 2025-11-17T21:28:48+00:00 hourly 0.9 https://trial.medpath.com/news/astrazeneca-and-sun-pharma-partner-to-expand-access-to-hyperkalaemia-treatment-in-india 2025-11-17T21:26:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/astrazeneca-and-sun-pharma-partner-to-expand-access-to-hyperkalaemia-treatment-in-india 2025-11-17T21:26:27+00:00 hourly 0.9 https://trial.medpath.com/news/abbvie-s-lupron-depot-receives-health-canada-approval-for-new-6-month-dosing-option-in-advanced-prostate-cancer 2025-11-17T21:26:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/abbvie-s-lupron-depot-receives-health-canada-approval-for-new-6-month-dosing-option-in-advanced-prostate-cancer 2025-11-17T21:26:24+00:00 hourly 0.9 https://trial.medpath.com/news/nerivio-wearable-device-shows-no-tachyphylaxis-in-3-year-migraine-study 2025-11-17T21:24:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nerivio-wearable-device-shows-no-tachyphylaxis-in-3-year-migraine-study 2025-11-17T21:24:59+00:00 hourly 0.9 https://trial.medpath.com/news/is4s-secures-direct-to-phase-ii-sbir-contract-for-advanced-fireset-system-development 2025-11-17T21:23:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/is4s-secures-direct-to-phase-ii-sbir-contract-for-advanced-fireset-system-development 2025-11-17T21:23:34+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-first-perjeta-biosimilar-as-shanghai-henlius-and-organon-secure-interchangeable-status 2025-11-17T21:22:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-first-perjeta-biosimilar-as-shanghai-henlius-and-organon-secure-interchangeable-status 2025-11-17T21:22:34+00:00 hourly 0.9 https://trial.medpath.com/news/nih-grant-terminations-disrupt-383-clinical-trials-affecting-over-74000-participants 2025-11-17T21:22:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nih-grant-terminations-disrupt-383-clinical-trials-affecting-over-74000-participants 2025-11-17T21:22:31+00:00 hourly 0.9 https://trial.medpath.com/news/crispr-gene-editing-reverses-chemotherapy-resistance-in-lung-cancer-by-targeting-nrf2 2025-11-17T21:22:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/crispr-gene-editing-reverses-chemotherapy-resistance-in-lung-cancer-by-targeting-nrf2 2025-11-17T21:22:19+00:00 hourly 0.9 https://trial.medpath.com/news/liquidia-s-yutrepia-achieves-commercial-success-with-51-7m-q3-sales-attracting-major-biotech-fund-investment 2025-11-17T21:20:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/liquidia-s-yutrepia-achieves-commercial-success-with-51-7m-q3-sales-attracting-major-biotech-fund-investment 2025-11-17T21:20:13+00:00 hourly 0.9 https://trial.medpath.com/news/imbria-pharmaceuticals-secures-extended-series-b-funding-to-advance-first-in-class-cardiovascular-therapy-ninerafaxstat 2025-11-17T17:35:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/imbria-pharmaceuticals-secures-extended-series-b-funding-to-advance-first-in-class-cardiovascular-therapy-ninerafaxstat 2025-11-17T17:35:58+00:00 hourly 0.9 https://trial.medpath.com/news/4d-molecular-therapeutics-appoints-kristian-humer-as-cfo-as-company-advances-phase-iii-retinal-disease-programs 2025-11-17T17:35:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/4d-molecular-therapeutics-appoints-kristian-humer-as-cfo-as-company-advances-phase-iii-retinal-disease-programs 2025-11-17T17:35:00+00:00 hourly 0.9 https://trial.medpath.com/news/omeros-secures-240m-novo-nordisk-deal-as-narsoplimab-approaches-fda-approval-for-tatma 2025-11-17T17:34:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/omeros-secures-240m-novo-nordisk-deal-as-narsoplimab-approaches-fda-approval-for-tatma 2025-11-17T17:34:55+00:00 hourly 0.9 https://trial.medpath.com/news/profluent-bio-partners-with-rsrt-to-develop-ai-designed-gene-editors-for-rett-syndrome 2025-11-17T17:30:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/profluent-bio-partners-with-rsrt-to-develop-ai-designed-gene-editors-for-rett-syndrome 2025-11-17T17:30:43+00:00 hourly 0.9 https://trial.medpath.com/news/novo-nordisk-slashes-wegovy-and-ozempic-prices-for-cash-paying-patients 2025-11-17T17:29:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novo-nordisk-slashes-wegovy-and-ozempic-prices-for-cash-paying-patients 2025-11-17T17:29:00+00:00 hourly 0.9 https://trial.medpath.com/news/acumen-pharmaceuticals-initiates-open-label-extension-study-for-alzheimer-s-drug-sabirnetug 2025-11-17T17:28:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/acumen-pharmaceuticals-initiates-open-label-extension-study-for-alzheimer-s-drug-sabirnetug 2025-11-17T17:28:41+00:00 hourly 0.9 https://trial.medpath.com/news/acuitas-therapeutics-advances-next-generation-lipid-nanoparticle-technology-with-enhanced-potency-and-targeted-delivery 2025-11-17T17:27:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/acuitas-therapeutics-advances-next-generation-lipid-nanoparticle-technology-with-enhanced-potency-and-targeted-delivery 2025-11-17T17:27:15+00:00 hourly 0.9 https://trial.medpath.com/news/recode-therapeutics-advances-phase-2-trial-of-inhaled-cftr-mrna-therapy-rct2100-combined-with-ivacaftor-for-cystic-fibrosis 2025-11-17T17:27:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/recode-therapeutics-advances-phase-2-trial-of-inhaled-cftr-mrna-therapy-rct2100-combined-with-ivacaftor-for-cystic-fibrosis 2025-11-17T17:27:13+00:00 hourly 0.9 https://trial.medpath.com/news/masimo-wins-634-million-patent-verdict-against-apple-over-heart-rate-monitoring-technology 2025-11-17T17:27:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/masimo-wins-634-million-patent-verdict-against-apple-over-heart-rate-monitoring-technology 2025-11-17T17:27:08+00:00 hourly 0.9 https://trial.medpath.com/news/angiex-raises-31-million-to-advance-first-in-class-nuclear-delivered-adc-agx101-through-phase-1-trial 2025-11-17T17:25:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/angiex-raises-31-million-to-advance-first-in-class-nuclear-delivered-adc-agx101-through-phase-1-trial 2025-11-17T17:25:54+00:00 hourly 0.9 https://trial.medpath.com/news/oceanic-stroke-phase-3-trial-advances-factor-xia-inhibitor-asundexian-for-secondary-stroke-prevention 2025-11-17T17:25:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oceanic-stroke-phase-3-trial-advances-factor-xia-inhibitor-asundexian-for-secondary-stroke-prevention 2025-11-17T17:25:38+00:00 hourly 0.9 https://trial.medpath.com/news/biotheryx-completes-enrollment-in-phase-1a-trial-of-first-in-class-cdk4-6-degrader-btx-9341-for-hr-her2-breast-cancer 2025-11-17T17:25:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biotheryx-completes-enrollment-in-phase-1a-trial-of-first-in-class-cdk4-6-degrader-btx-9341-for-hr-her2-breast-cancer 2025-11-17T17:25:06+00:00 hourly 0.9 https://trial.medpath.com/news/broken-string-biosciences-appoints-new-ceo-to-commercialize-gene-editing-safety-platform 2025-11-17T17:24:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/broken-string-biosciences-appoints-new-ceo-to-commercialize-gene-editing-safety-platform 2025-11-17T17:24:48+00:00 hourly 0.9 https://trial.medpath.com/news/artios-pharma-raises-115m-series-d-to-advance-dna-damage-response-cancer-therapies 2025-11-17T17:24:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/artios-pharma-raises-115m-series-d-to-advance-dna-damage-response-cancer-therapies 2025-11-17T17:24:22+00:00 hourly 0.9 https://trial.medpath.com/news/biolinerx-secures-key-patent-for-glix1-cancer-therapy-covering-over-90-of-cancer-types 2025-11-17T17:24:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biolinerx-secures-key-patent-for-glix1-cancer-therapy-covering-over-90-of-cancer-types 2025-11-17T17:24:03+00:00 hourly 0.9 https://trial.medpath.com/news/ohio-state-university-launches-400000-psychedelic-crisis-training-program-for-healthcare-professionals 2025-11-17T17:23:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ohio-state-university-launches-400000-psychedelic-crisis-training-program-for-healthcare-professionals 2025-11-17T17:23:49+00:00 hourly 0.9 https://trial.medpath.com/news/adaptimmune-undergoes-major-leadership-restructuring-following-nasdaq-delisting-and-asset-divestiture 2025-11-17T17:23:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/adaptimmune-undergoes-major-leadership-restructuring-following-nasdaq-delisting-and-asset-divestiture 2025-11-17T17:23:14+00:00 hourly 0.9 https://trial.medpath.com/news/johnson-johnson-acquires-halda-therapeutics-for-3-05-billion-to-strengthen-cancer-pipeline 2025-11-17T17:22:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/johnson-johnson-acquires-halda-therapeutics-for-3-05-billion-to-strengthen-cancer-pipeline 2025-11-17T17:22:03+00:00 hourly 0.9 https://trial.medpath.com/news/scottish-brain-sciences-opens-third-clinical-research-center-in-aberdeen-to-advance-alzheimer-s-early-detection-studies 2025-11-17T17:22:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/scottish-brain-sciences-opens-third-clinical-research-center-in-aberdeen-to-advance-alzheimer-s-early-detection-studies 2025-11-17T17:22:01+00:00 hourly 0.9 https://trial.medpath.com/news/artios-pharma-raises-115m-series-d-to-advance-next-generation-dna-damage-repair-cancer-therapies 2025-11-17T17:21:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/artios-pharma-raises-115m-series-d-to-advance-next-generation-dna-damage-repair-cancer-therapies 2025-11-17T17:21:58+00:00 hourly 0.9 https://trial.medpath.com/news/pluristyx-secures-1-4m-from-breakthrough-t1d-to-develop-universal-immune-cloaked-cell-line-for-type-1-diabetes-therapies 2025-11-17T17:21:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pluristyx-secures-1-4m-from-breakthrough-t1d-to-develop-universal-immune-cloaked-cell-line-for-type-1-diabetes-therapies 2025-11-17T17:21:00+00:00 hourly 0.9 https://trial.medpath.com/news/biorestorative-secures-fda-type-b-meeting-to-discuss-accelerated-approval-pathway-for-brtx-100-stem-cell-therapy 2025-11-17T17:20:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biorestorative-secures-fda-type-b-meeting-to-discuss-accelerated-approval-pathway-for-brtx-100-stem-cell-therapy 2025-11-17T17:20:05+00:00 hourly 0.9 https://trial.medpath.com/news/merus-and-halozyme-partner-to-develop-subcutaneous-formulation-of-petosemtamab-for-cancer-treatment 2025-11-17T17:19:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/merus-and-halozyme-partner-to-develop-subcutaneous-formulation-of-petosemtamab-for-cancer-treatment 2025-11-17T17:19:41+00:00 hourly 0.9 https://trial.medpath.com/news/who-approves-international-name-for-anixa-s-novel-car-t-therapy-targeting-ovarian-cancer 2025-11-17T17:19:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/who-approves-international-name-for-anixa-s-novel-car-t-therapy-targeting-ovarian-cancer 2025-11-17T17:19:26+00:00 hourly 0.9 https://trial.medpath.com/news/ema-launches-streamlined-process-to-fast-track-critical-medicines-and-vaccines-for-public-health-threats 2025-11-17T17:19:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ema-launches-streamlined-process-to-fast-track-critical-medicines-and-vaccines-for-public-health-threats 2025-11-17T17:19:21+00:00 hourly 0.9 https://trial.medpath.com/news/galmed-reports-promising-triple-drug-combination-for-gastrointestinal-cancers 2025-11-17T17:18:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/galmed-reports-promising-triple-drug-combination-for-gastrointestinal-cancers 2025-11-17T17:18:14+00:00 hourly 0.9 https://trial.medpath.com/news/solve-therapeutics-secures-120-million-to-advance-next-generation-adc-platform-for-solid-tumors 2025-11-17T17:18:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/solve-therapeutics-secures-120-million-to-advance-next-generation-adc-platform-for-solid-tumors 2025-11-17T17:18:12+00:00 hourly 0.9 https://trial.medpath.com/news/pfizer-launches-cgrp-receptor-antagonist-rimegepant-for-migraine-treatment-in-india 2025-11-17T17:18:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pfizer-launches-cgrp-receptor-antagonist-rimegepant-for-migraine-treatment-in-india 2025-11-17T17:18:09+00:00 hourly 0.9 https://trial.medpath.com/news/eu-funded-transcan-3-project-advances-personalized-t-cell-therapy-for-esophageal-cancer 2025-11-17T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eu-funded-transcan-3-project-advances-personalized-t-cell-therapy-for-esophageal-cancer 2025-11-17T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/nxera-pharma-announces-strategic-restructuring-with-15-workforce-reduction-to-focus-on-gpcr-pipeline 2025-11-17T13:24:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nxera-pharma-announces-strategic-restructuring-with-15-workforce-reduction-to-focus-on-gpcr-pipeline 2025-11-17T13:24:30+00:00 hourly 0.9 https://trial.medpath.com/news/accession-therapeutics-doses-first-patient-in-phase-1-trial-of-novel-tumor-activated-viral-immunotherapy-trocept-01 2025-11-17T13:23:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/accession-therapeutics-doses-first-patient-in-phase-1-trial-of-novel-tumor-activated-viral-immunotherapy-trocept-01 2025-11-17T13:23:52+00:00 hourly 0.9 https://trial.medpath.com/news/itm-receives-fda-fast-track-designation-for-itm-94-diagnostic-agent-in-clear-cell-renal-cell-carcinoma 2025-11-17T13:21:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/itm-receives-fda-fast-track-designation-for-itm-94-diagnostic-agent-in-clear-cell-renal-cell-carcinoma 2025-11-17T13:21:07+00:00 hourly 0.9 https://trial.medpath.com/news/ziihera-demonstrates-superior-efficacy-in-phase-3-trial-for-her2-positive-gastroesophageal-cancer 2025-11-17T13:20:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ziihera-demonstrates-superior-efficacy-in-phase-3-trial-for-her2-positive-gastroesophageal-cancer 2025-11-17T13:20:33+00:00 hourly 0.9 https://trial.medpath.com/news/switching-from-ibrutinib-to-zanubrutinib-maintains-efficacy-and-safety-in-waldenstrom-macroglobulinemia-patients 2025-11-17T13:19:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/switching-from-ibrutinib-to-zanubrutinib-maintains-efficacy-and-safety-in-waldenstrom-macroglobulinemia-patients 2025-11-17T13:19:49+00:00 hourly 0.9 https://trial.medpath.com/news/world-s-first-lung-cancer-prevention-vaccine-lungvax-receives-ps2-06-million-for-phase-i-clinical-trial 2025-11-17T13:19:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/world-s-first-lung-cancer-prevention-vaccine-lungvax-receives-ps2-06-million-for-phase-i-clinical-trial 2025-11-17T13:19:44+00:00 hourly 0.9 https://trial.medpath.com/news/kazakhstan-s-anti-cancer-drug-targeting-kras-mutant-tumors-advances-to-phase-2026-clinical-trials 2025-11-17T13:19:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kazakhstan-s-anti-cancer-drug-targeting-kras-mutant-tumors-advances-to-phase-2026-clinical-trials 2025-11-17T13:19:38+00:00 hourly 0.9 https://trial.medpath.com/news/captain-t-cell-secures-eur20-million-to-advance-next-generation-tcr-t-therapies-for-solid-tumors 2025-11-17T09:22:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/captain-t-cell-secures-eur20-million-to-advance-next-generation-tcr-t-therapies-for-solid-tumors 2025-11-17T09:22:28+00:00 hourly 0.9 https://trial.medpath.com/news/agomab-s-ontunisertib-achieves-primary-safety-endpoint-in-first-in-class-phase-2a-trial-for-fibrostenosing-crohn-s-disease 2025-11-17T09:21:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/agomab-s-ontunisertib-achieves-primary-safety-endpoint-in-first-in-class-phase-2a-trial-for-fibrostenosing-crohn-s-disease 2025-11-17T09:21:46+00:00 hourly 0.9 https://trial.medpath.com/news/ybrain-launches-enhanced-at-home-electronic-depression-treatment-device-with-62-8-remission-rate 2025-11-17T09:21:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ybrain-launches-enhanced-at-home-electronic-depression-treatment-device-with-62-8-remission-rate 2025-11-17T09:21:24+00:00 hourly 0.9 https://trial.medpath.com/news/sandoz-launches-first-fda-approved-multiple-sclerosis-biosimilar-tyruko-in-us-market 2025-11-17T09:20:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sandoz-launches-first-fda-approved-multiple-sclerosis-biosimilar-tyruko-in-us-market 2025-11-17T09:20:55+00:00 hourly 0.9 https://trial.medpath.com/news/european-regulators-recommend-approval-of-incyte-s-minjuvi-for-relapsed-follicular-lymphoma 2025-11-17T09:19:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/european-regulators-recommend-approval-of-incyte-s-minjuvi-for-relapsed-follicular-lymphoma 2025-11-17T09:19:44+00:00 hourly 0.9 https://trial.medpath.com/news/formycon-achieves-technical-proof-of-similarity-for-dupilumab-biosimilar-fyb208-targeting-20-billion-market 2025-11-17T09:19:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/formycon-achieves-technical-proof-of-similarity-for-dupilumab-biosimilar-fyb208-targeting-20-billion-market 2025-11-17T09:19:41+00:00 hourly 0.9 https://trial.medpath.com/news/nice-initiates-appraisals-for-two-cancer-immunotherapies-sasanlimab-bcg-combination-and-cemiplimab-adjuvant-treatment 2025-11-17T08:55:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nice-initiates-appraisals-for-two-cancer-immunotherapies-sasanlimab-bcg-combination-and-cemiplimab-adjuvant-treatment 2025-11-17T08:55:00+00:00 hourly 0.9 https://trial.medpath.com/news/wellscare-expands-iaso-wearable-cold-laser-therapy-to-thailand-through-strategic-partnership 2025-11-17T05:20:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/wellscare-expands-iaso-wearable-cold-laser-therapy-to-thailand-through-strategic-partnership 2025-11-17T05:20:07+00:00 hourly 0.9 https://trial.medpath.com/news/bioxyne-secures-1-7m-scottish-government-funding-to-establish-uk-medicinal-cannabis-manufacturing-facility 2025-11-17T05:19:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bioxyne-secures-1-7m-scottish-government-funding-to-establish-uk-medicinal-cannabis-manufacturing-facility 2025-11-17T05:19:06+00:00 hourly 0.9 https://trial.medpath.com/news/spravato-receives-fda-approval-as-first-monotherapy-for-treatment-resistant-depression 2025-11-17T05:18:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/spravato-receives-fda-approval-as-first-monotherapy-for-treatment-resistant-depression 2025-11-17T05:18:41+00:00 hourly 0.9 https://trial.medpath.com/news/golexanolone-shows-promise-as-early-disease-modifying-treatment-for-parkinson-s-disease 2025-11-17T03:32:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/golexanolone-shows-promise-as-early-disease-modifying-treatment-for-parkinson-s-disease 2025-11-17T03:32:00+00:00 hourly 0.9 https://trial.medpath.com/news/annovis-bio-s-buntanetap-halts-cognitive-decline-in-parkinson-s-patients-shows-strongest-effect-in-amyloid-co-pathology-subgroup 2025-11-17T02:02:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/annovis-bio-s-buntanetap-halts-cognitive-decline-in-parkinson-s-patients-shows-strongest-effect-in-amyloid-co-pathology-subgroup 2025-11-17T02:02:00+00:00 hourly 0.9 https://trial.medpath.com/news/korean-biotech-platforms-drive-record-13-5-billion-in-technology-exports 2025-11-17T01:19:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/korean-biotech-platforms-drive-record-13-5-billion-in-technology-exports 2025-11-17T01:19:43+00:00 hourly 0.9 https://trial.medpath.com/news/crispr-cas9-gene-editing-shows-promise-for-treating-collagen-disorders 2025-11-17T01:18:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/crispr-cas9-gene-editing-shows-promise-for-treating-collagen-disorders 2025-11-17T01:18:57+00:00 hourly 0.9 https://trial.medpath.com/news/pharmather-secures-exclusive-rights-to-long-acting-injectable-ketamine-technology-for-treatment-resistant-depression 2025-11-17T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pharmather-secures-exclusive-rights-to-long-acting-injectable-ketamine-technology-for-treatment-resistant-depression 2025-11-17T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/pulsed-field-ablation-demonstrates-superior-efficacy-and-safety-profile-in-landmark-sham-controlled-trial-and-real-world-registry 2025-11-17T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pulsed-field-ablation-demonstrates-superior-efficacy-and-safety-profile-in-landmark-sham-controlled-trial-and-real-world-registry 2025-11-17T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/epirium-bio-gains-fda-alignment-for-phase-2b-trial-of-first-in-class-sarcopenia-treatment-mf-300 2025-11-17T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/epirium-bio-gains-fda-alignment-for-phase-2b-trial-of-first-in-class-sarcopenia-treatment-mf-300 2025-11-17T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/ivonescimab-receives-china-approval-for-egfr-mutated-nsclc-demonstrates-superior-efficacy-across-multiple-cancer-types 2025-11-17T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ivonescimab-receives-china-approval-for-egfr-mutated-nsclc-demonstrates-superior-efficacy-across-multiple-cancer-types 2025-11-17T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/duke-health-reports-100-survival-rate-in-20-year-breast-cancer-vaccine-trial 2025-11-16T17:19:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/duke-health-reports-100-survival-rate-in-20-year-breast-cancer-vaccine-trial 2025-11-16T17:19:39+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-accelerated-approval-for-elevidys-gene-therapy-first-treatment-for-duchenne-muscular-dystrophy 2025-11-16T17:18:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-accelerated-approval-for-elevidys-gene-therapy-first-treatment-for-duchenne-muscular-dystrophy 2025-11-16T17:18:16+00:00 hourly 0.9 https://trial.medpath.com/news/tumor-infiltrating-lymphocyte-therapy-shows-promise-in-advanced-melanoma-with-sustained-response-rates 2025-11-16T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tumor-infiltrating-lymphocyte-therapy-shows-promise-in-advanced-melanoma-with-sustained-response-rates 2025-11-16T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/zhongsheng-pharmaceutical-advances-pediatric-angladivir-granules-to-phase-iii-for-influenza-a-treatment 2025-11-16T13:21:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/zhongsheng-pharmaceutical-advances-pediatric-angladivir-granules-to-phase-iii-for-influenza-a-treatment 2025-11-16T13:21:27+00:00 hourly 0.9 https://trial.medpath.com/news/cdsco-orders-dr-reddy-s-to-revise-vonoprazan-phase-iv-trial-protocol-over-inadequate-sample-size 2025-11-16T09:19:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cdsco-orders-dr-reddy-s-to-revise-vonoprazan-phase-iv-trial-protocol-over-inadequate-sample-size 2025-11-16T09:19:45+00:00 hourly 0.9 https://trial.medpath.com/news/aav-delivered-sirna-therapy-shows-promise-for-targeting-mucus-overproduction-in-asthma 2025-11-16T09:19:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aav-delivered-sirna-therapy-shows-promise-for-targeting-mucus-overproduction-in-asthma 2025-11-16T09:19:40+00:00 hourly 0.9 https://trial.medpath.com/news/obagi-medical-presents-pivotal-hyaluronic-acid-filler-data-at-asds-meeting-demonstrating-non-inferiority-to-juvederm-voluma 2025-11-16T09:18:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/obagi-medical-presents-pivotal-hyaluronic-acid-filler-data-at-asds-meeting-demonstrating-non-inferiority-to-juvederm-voluma 2025-11-16T09:18:55+00:00 hourly 0.9 https://trial.medpath.com/news/pharvaris-reports-92-4-reduction-in-hereditary-angioedema-attacks-with-deucrictibant-in-long-term-study 2025-11-16T05:19:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pharvaris-reports-92-4-reduction-in-hereditary-angioedema-attacks-with-deucrictibant-in-long-term-study 2025-11-16T05:19:31+00:00 hourly 0.9 https://trial.medpath.com/news/engineered-aav-variants-show-10-fold-improvement-in-vascular-gene-delivery 2025-11-16T01:19:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/engineered-aav-variants-show-10-fold-improvement-in-vascular-gene-delivery 2025-11-16T01:19:43+00:00 hourly 0.9 https://trial.medpath.com/news/nad-supplement-shows-early-promise-for-long-covid-fatigue-and-brain-fog-in-clinical-trial 2025-11-16T01:19:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nad-supplement-shows-early-promise-for-long-covid-fatigue-and-brain-fog-in-clinical-trial 2025-11-16T01:19:38+00:00 hourly 0.9 https://trial.medpath.com/news/brainxell-s-bxt-110-shows-promising-preclinical-results-for-parkinson-s-disease-cell-therapy 2025-11-16T01:19:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/brainxell-s-bxt-110-shows-promising-preclinical-results-for-parkinson-s-disease-cell-therapy 2025-11-16T01:19:35+00:00 hourly 0.9 https://trial.medpath.com/news/facet-life-sciences-and-xcancer-form-strategic-partnership-to-accelerate-theranostic-drug-development 2025-11-16T01:19:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/facet-life-sciences-and-xcancer-form-strategic-partnership-to-accelerate-theranostic-drug-development 2025-11-16T01:19:22+00:00 hourly 0.9 https://trial.medpath.com/news/maxx-orthopedics-secures-fda-clearance-for-two-advanced-orthopedic-implant-systems 2025-11-16T01:19:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/maxx-orthopedics-secures-fda-clearance-for-two-advanced-orthopedic-implant-systems 2025-11-16T01:19:19+00:00 hourly 0.9 https://trial.medpath.com/news/curevac-reports-eur371-6-million-net-income-following-gsk-partnership-and-strategic-restructuring 2025-11-15T21:21:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/curevac-reports-eur371-6-million-net-income-following-gsk-partnership-and-strategic-restructuring 2025-11-15T21:21:45+00:00 hourly 0.9 https://trial.medpath.com/news/fda-rejects-uniqure-s-amt-130-gene-therapy-data-for-huntington-s-disease-bla-submission 2025-11-15T21:21:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-rejects-uniqure-s-amt-130-gene-therapy-data-for-huntington-s-disease-bla-submission 2025-11-15T21:21:06+00:00 hourly 0.9 https://trial.medpath.com/news/mangoceuticals-launches-direct-access-programs-for-zepbound-and-wegovy-through-eli-lilly-and-novo-nordisk-partnerships 2025-11-15T17:21:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mangoceuticals-launches-direct-access-programs-for-zepbound-and-wegovy-through-eli-lilly-and-novo-nordisk-partnerships 2025-11-15T17:21:43+00:00 hourly 0.9 https://trial.medpath.com/news/trinity-biotech-partners-with-bioinformatics-company-to-advance-epicapture-prostate-cancer-test 2025-11-15T17:20:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/trinity-biotech-partners-with-bioinformatics-company-to-advance-epicapture-prostate-cancer-test 2025-11-15T17:20:20+00:00 hourly 0.9 https://trial.medpath.com/news/curis-to-present-emavusertib-clinical-data-in-cns-lymphoma-at-society-for-neuro-oncology-meeting 2025-11-15T13:23:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/curis-to-present-emavusertib-clinical-data-in-cns-lymphoma-at-society-for-neuro-oncology-meeting 2025-11-15T13:23:07+00:00 hourly 0.9 https://trial.medpath.com/news/gates-foundation-awards-13-5-million-to-slash-monoclonal-antibody-costs-from-100-to-10-per-gram 2025-11-15T13:21:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gates-foundation-awards-13-5-million-to-slash-monoclonal-antibody-costs-from-100-to-10-per-gram 2025-11-15T13:21:51+00:00 hourly 0.9 https://trial.medpath.com/news/tb-alliance-to-present-phase-2-results-for-sorfequiline-next-generation-tb-drug-candidate 2025-11-15T09:31:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tb-alliance-to-present-phase-2-results-for-sorfequiline-next-generation-tb-drug-candidate 2025-11-15T09:31:33+00:00 hourly 0.9 https://trial.medpath.com/news/trevi-therapeutics-advances-chronic-cough-drug-haduvio-toward-phase-3-trials-with-extended-cash-runway-through-2028 2025-11-15T09:29:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/trevi-therapeutics-advances-chronic-cough-drug-haduvio-toward-phase-3-trials-with-extended-cash-runway-through-2028 2025-11-15T09:29:00+00:00 hourly 0.9 https://trial.medpath.com/news/gate-bioscience-raises-65-million-series-b-to-advance-novel-oral-molecular-gate-therapies-into-clinical-trials 2025-11-15T05:20:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gate-bioscience-raises-65-million-series-b-to-advance-novel-oral-molecular-gate-therapies-into-clinical-trials 2025-11-15T05:20:54+00:00 hourly 0.9 https://trial.medpath.com/news/windtree-therapeutics-strengthens-patent-portfolio-for-heart-failure-drug-istaroxime-with-international-approvals 2025-11-15T05:20:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/windtree-therapeutics-strengthens-patent-portfolio-for-heart-failure-drug-istaroxime-with-international-approvals 2025-11-15T05:20:47+00:00 hourly 0.9 https://trial.medpath.com/news/biomimetic-mrna-delivery-system-achieves-20-fold-improvement-in-tumor-targeting-for-colorectal-cancer 2025-11-15T05:20:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biomimetic-mrna-delivery-system-achieves-20-fold-improvement-in-tumor-targeting-for-colorectal-cancer 2025-11-15T05:20:13+00:00 hourly 0.9 https://trial.medpath.com/news/repare-therapeutics-agrees-to-1-82-per-share-acquisition-by-xenotherapeutics 2025-11-15T01:27:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/repare-therapeutics-agrees-to-1-82-per-share-acquisition-by-xenotherapeutics 2025-11-15T01:27:23+00:00 hourly 0.9 https://trial.medpath.com/news/curative-surgery-after-immunotherapy-reduces-death-risk-by-85-in-advanced-liver-cancer 2025-11-15T01:23:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/curative-surgery-after-immunotherapy-reduces-death-risk-by-85-in-advanced-liver-cancer 2025-11-15T01:23:14+00:00 hourly 0.9 https://trial.medpath.com/news/magnetic-nanoparticles-enhance-amphotericin-b-delivery-against-leishmaniasis-with-reduced-toxicity 2025-11-15T01:21:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/magnetic-nanoparticles-enhance-amphotericin-b-delivery-against-leishmaniasis-with-reduced-toxicity 2025-11-15T01:21:40+00:00 hourly 0.9 https://trial.medpath.com/news/enzymit-and-cosun-achieve-world-s-first-pilot-scale-cell-free-hyaluronic-acid-production 2025-11-15T01:20:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/enzymit-and-cosun-achieve-world-s-first-pilot-scale-cell-free-hyaluronic-acid-production 2025-11-15T01:20:29+00:00 hourly 0.9 https://trial.medpath.com/news/orasis-pharmaceuticals-expands-qlosi-access-with-new-starter-packs-following-strong-market-adoption 2025-11-14T21:26:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/orasis-pharmaceuticals-expands-qlosi-access-with-new-starter-packs-following-strong-market-adoption 2025-11-14T21:26:17+00:00 hourly 0.9 https://trial.medpath.com/news/biotron-s-bit-hbv001-shows-superior-antiviral-activity-against-hepatitis-b-compared-to-standard-therapy 2025-11-14T21:25:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biotron-s-bit-hbv001-shows-superior-antiviral-activity-against-hepatitis-b-compared-to-standard-therapy 2025-11-14T21:25:35+00:00 hourly 0.9 https://trial.medpath.com/news/revolutionary-car-t-therapy-shows-promise-for-autoimmune-disease-treatment 2025-11-14T17:32:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/revolutionary-car-t-therapy-shows-promise-for-autoimmune-disease-treatment 2025-11-14T17:32:50+00:00 hourly 0.9 https://trial.medpath.com/news/anavex-life-sciences-shares-plummet-50-following-ema-rejection-of-alzheimer-s-drug-blarcamesine 2025-11-14T17:31:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/anavex-life-sciences-shares-plummet-50-following-ema-rejection-of-alzheimer-s-drug-blarcamesine 2025-11-14T17:31:06+00:00 hourly 0.9 https://trial.medpath.com/news/fortress-biotech-reports-strong-q3-2025-results-with-strategic-asset-sales-and-pipeline-advances 2025-11-14T17:27:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fortress-biotech-reports-strong-q3-2025-results-with-strategic-asset-sales-and-pipeline-advances 2025-11-14T17:27:02+00:00 hourly 0.9 https://trial.medpath.com/news/general-proximity-partners-with-daiichi-sankyo-on-multi-target-oncology-collaboration-using-omnitac-platform 2025-11-14T17:26:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/general-proximity-partners-with-daiichi-sankyo-on-multi-target-oncology-collaboration-using-omnitac-platform 2025-11-14T17:26:29+00:00 hourly 0.9 https://trial.medpath.com/news/third-arc-bio-partners-with-adagene-to-develop-masked-cd3-t-cell-engagers-for-solid-tumor-treatment 2025-11-14T17:25:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/third-arc-bio-partners-with-adagene-to-develop-masked-cd3-t-cell-engagers-for-solid-tumor-treatment 2025-11-14T17:25:54+00:00 hourly 0.9 https://trial.medpath.com/news/samson-clinical-completes-enrollment-for-phase-iii-sublingual-minoxidil-trial-in-male-pattern-hair-loss 2025-11-14T17:25:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/samson-clinical-completes-enrollment-for-phase-iii-sublingual-minoxidil-trial-in-male-pattern-hair-loss 2025-11-14T17:25:40+00:00 hourly 0.9 https://trial.medpath.com/news/mhra-approves-leqembi-iv-maintenance-therapy-as-additional-treatment-option-for-alzheimer-s-disease 2025-11-14T17:23:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mhra-approves-leqembi-iv-maintenance-therapy-as-additional-treatment-option-for-alzheimer-s-disease 2025-11-14T17:23:50+00:00 hourly 0.9 https://trial.medpath.com/news/bristol-myers-squibb-and-j-j-halt-phase-3-trial-of-blood-thinner-milvexian-in-acute-coronary-syndrome 2025-11-14T17:20:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bristol-myers-squibb-and-j-j-halt-phase-3-trial-of-blood-thinner-milvexian-in-acute-coronary-syndrome 2025-11-14T17:20:37+00:00 hourly 0.9 https://trial.medpath.com/news/singapore-launches-phase-iii-of-national-precision-medicine-programme-to-enroll-400000-patients 2025-11-14T17:20:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/singapore-launches-phase-iii-of-national-precision-medicine-programme-to-enroll-400000-patients 2025-11-14T17:20:32+00:00 hourly 0.9 https://trial.medpath.com/news/zimmer-biomet-receives-fda-clearance-for-enhanced-rosa-knee-robotic-surgery-system 2025-11-14T17:20:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/zimmer-biomet-receives-fda-clearance-for-enhanced-rosa-knee-robotic-surgery-system 2025-11-14T17:20:26+00:00 hourly 0.9 https://trial.medpath.com/news/european-regulators-recommend-approval-for-waskyra-gene-therapy-for-rare-wiskott-aldrich-syndrome 2025-11-14T17:19:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/european-regulators-recommend-approval-for-waskyra-gene-therapy-for-rare-wiskott-aldrich-syndrome 2025-11-14T17:19:14+00:00 hourly 0.9 https://trial.medpath.com/news/ema-recommends-first-gene-therapy-for-wiskott-aldrich-syndrome 2025-11-14T17:19:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ema-recommends-first-gene-therapy-for-wiskott-aldrich-syndrome 2025-11-14T17:19:02+00:00 hourly 0.9 https://trial.medpath.com/news/sas-launches-clinical-acceleration-platform-to-streamline-drug-development-and-regulatory-submissions 2025-11-14T17:18:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sas-launches-clinical-acceleration-platform-to-streamline-drug-development-and-regulatory-submissions 2025-11-14T17:18:41+00:00 hourly 0.9 https://trial.medpath.com/news/biocon-explores-4-5-billion-merger-of-biologics-unit-with-parent-company-as-ipo-alternative 2025-11-14T14:42:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biocon-explores-4-5-billion-merger-of-biologics-unit-with-parent-company-as-ipo-alternative 2025-11-14T14:42:00+00:00 hourly 0.9 https://trial.medpath.com/news/medicxi-closes-eur500m-fund-v-to-accelerate-asset-centric-biotech-investments 2025-11-14T13:26:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/medicxi-closes-eur500m-fund-v-to-accelerate-asset-centric-biotech-investments 2025-11-14T13:26:35+00:00 hourly 0.9 https://trial.medpath.com/news/boost-pharma-advances-stem-cell-therapy-bt-101-for-osteogenesis-imperfecta-with-positive-two-year-data-and-4-4m-funding 2025-11-14T13:26:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/boost-pharma-advances-stem-cell-therapy-bt-101-for-osteogenesis-imperfecta-with-positive-two-year-data-and-4-4m-funding 2025-11-14T13:26:21+00:00 hourly 0.9 https://trial.medpath.com/news/stat-inhibitor-pipeline-expands-with-22-drugs-across-18-companies-targeting-cancer-and-inflammatory-diseases 2025-11-14T13:22:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/stat-inhibitor-pipeline-expands-with-22-drugs-across-18-companies-targeting-cancer-and-inflammatory-diseases 2025-11-14T13:22:59+00:00 hourly 0.9 https://trial.medpath.com/news/appili-therapeutics-secures-40-million-niaid-contract-for-antifungal-vaccine-development 2025-11-14T13:22:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/appili-therapeutics-secures-40-million-niaid-contract-for-antifungal-vaccine-development 2025-11-14T13:22:57+00:00 hourly 0.9 https://trial.medpath.com/news/lundbeck-seeks-asian-market-approval-for-vyepti-migraine-prevention-therapy 2025-11-14T13:21:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lundbeck-seeks-asian-market-approval-for-vyepti-migraine-prevention-therapy 2025-11-14T13:21:39+00:00 hourly 0.9 https://trial.medpath.com/news/matisse-pharmaceuticals-advances-m6229-sepsis-treatment-with-positive-120-hour-infusion-trial-results 2025-11-14T13:20:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/matisse-pharmaceuticals-advances-m6229-sepsis-treatment-with-positive-120-hour-infusion-trial-results 2025-11-14T13:20:39+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-five-breakthrough-therapies-for-gastrointestinal-cancers-in-first-half-of-2025 2025-11-14T13:19:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-five-breakthrough-therapies-for-gastrointestinal-cancers-in-first-half-of-2025 2025-11-14T13:19:52+00:00 hourly 0.9 https://trial.medpath.com/news/prism-biolab-achieves-first-milestone-in-oncology-drug-discovery-partnership-with-ono-pharmaceutical 2025-11-14T13:19:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/prism-biolab-achieves-first-milestone-in-oncology-drug-discovery-partnership-with-ono-pharmaceutical 2025-11-14T13:19:44+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-omeros-yartemlea-as-first-treatment-for-rare-post-transplant-blood-disorder-ta-tma 2025-11-14T12:07:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-omeros-yartemlea-as-first-treatment-for-rare-post-transplant-blood-disorder-ta-tma 2025-11-14T12:07:00+00:00 hourly 0.9 https://trial.medpath.com/news/4teen4-pharmaceuticals-secures-eur55-million-to-advance-procizumab-in-cardiogenic-shock 2025-11-14T09:20:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/4teen4-pharmaceuticals-secures-eur55-million-to-advance-procizumab-in-cardiogenic-shock 2025-11-14T09:20:52+00:00 hourly 0.9 https://trial.medpath.com/news/diamyd-medical-s-phase-3-type-1-diabetes-trial-clears-final-safety-review-ahead-of-march-2026-readout 2025-11-14T09:20:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/diamyd-medical-s-phase-3-type-1-diabetes-trial-clears-final-safety-review-ahead-of-march-2026-readout 2025-11-14T09:20:04+00:00 hourly 0.9 https://trial.medpath.com/news/shield-therapeutics-initiates-phase-ii-trial-of-accrufer-for-pulmonary-arterial-hypertension-in-japan 2025-11-14T09:19:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/shield-therapeutics-initiates-phase-ii-trial-of-accrufer-for-pulmonary-arterial-hypertension-in-japan 2025-11-14T09:19:12+00:00 hourly 0.9 https://trial.medpath.com/news/biopharma-job-market-recovery-expected-by-late-2026-despite-current-downturn 2025-11-14T06:17:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biopharma-job-market-recovery-expected-by-late-2026-despite-current-downturn 2025-11-14T06:17:45+00:00 hourly 0.9 https://trial.medpath.com/news/palatin-technologies-advances-melanocortin-based-obesity-pipeline-with-18-2m-funding-and-boehringer-ingelheim-partnership 2025-11-14T05:22:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/palatin-technologies-advances-melanocortin-based-obesity-pipeline-with-18-2m-funding-and-boehringer-ingelheim-partnership 2025-11-14T05:22:17+00:00 hourly 0.9 https://trial.medpath.com/news/merck-nears-3-3-billion-acquisition-of-cidara-therapeutics-for-breakthrough-influenza-treatment 2025-11-14T05:21:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/merck-nears-3-3-billion-acquisition-of-cidara-therapeutics-for-breakthrough-influenza-treatment 2025-11-14T05:21:54+00:00 hourly 0.9 https://trial.medpath.com/news/dare-bioscience-advances-women-s-health-pipeline-with-near-term-revenue-launch-and-positive-phase-3-data 2025-11-14T05:21:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dare-bioscience-advances-women-s-health-pipeline-with-near-term-revenue-launch-and-positive-phase-3-data 2025-11-14T05:21:17+00:00 hourly 0.9 https://trial.medpath.com/news/cognito-therapeutics-and-wvu-launch-first-brain-health-collaboratory-to-accelerate-neurotherapy-development 2025-11-14T05:21:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cognito-therapeutics-and-wvu-launch-first-brain-health-collaboratory-to-accelerate-neurotherapy-development 2025-11-14T05:21:10+00:00 hourly 0.9 https://trial.medpath.com/news/tandemai-secures-22m-series-a-extension-to-advance-ai-powered-drug-discovery-platform 2025-11-14T05:19:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tandemai-secures-22m-series-a-extension-to-advance-ai-powered-drug-discovery-platform 2025-11-14T05:19:00+00:00 hourly 0.9 https://trial.medpath.com/news/regeneron-announces-2-billion-manufacturing-expansion-in-new-york-creating-1000-jobs 2025-11-14T05:18:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/regeneron-announces-2-billion-manufacturing-expansion-in-new-york-creating-1000-jobs 2025-11-14T05:18:46+00:00 hourly 0.9 https://trial.medpath.com/news/repare-therapeutics-agrees-to-1-82-per-share-acquisition-by-xenotherapeutics 2025-11-14T04:43:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/repare-therapeutics-agrees-to-1-82-per-share-acquisition-by-xenotherapeutics 2025-11-14T04:43:00+00:00 hourly 0.9 https://trial.medpath.com/news/imagenebio-advances-anti-ox40-antibody-img-007-with-protocol-amendment-for-phase-2b-atopic-dermatitis-trial 2025-11-14T01:31:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/imagenebio-advances-anti-ox40-antibody-img-007-with-protocol-amendment-for-phase-2b-atopic-dermatitis-trial 2025-11-14T01:31:42+00:00 hourly 0.9 https://trial.medpath.com/news/pfizer-reduces-biontech-stake-by-55-as-covid-vaccine-partnership-evolves 2025-11-14T01:27:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pfizer-reduces-biontech-stake-by-55-as-covid-vaccine-partnership-evolves 2025-11-14T01:27:27+00:00 hourly 0.9 https://trial.medpath.com/news/bryet-us-secures-patent-for-nanoporous-silicon-drug-delivery-platform-targeting-cancer-treatment-resistance 2025-11-14T01:27:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bryet-us-secures-patent-for-nanoporous-silicon-drug-delivery-platform-targeting-cancer-treatment-resistance 2025-11-14T01:27:25+00:00 hourly 0.9 https://trial.medpath.com/news/fennec-pharmaceuticals-announces-public-offering-to-fund-debt-reduction-and-operations 2025-11-14T01:23:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fennec-pharmaceuticals-announces-public-offering-to-fund-debt-reduction-and-operations 2025-11-14T01:23:55+00:00 hourly 0.9 https://trial.medpath.com/news/nanobiotix-advances-curadigm-nanoprimer-platform-with-new-patent-filings-and-promising-vaccine-combination-data 2025-11-14T01:23:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nanobiotix-advances-curadigm-nanoprimer-platform-with-new-patent-filings-and-promising-vaccine-combination-data 2025-11-14T01:23:45+00:00 hourly 0.9 https://trial.medpath.com/news/amneal-secures-fda-approval-for-first-generic-iohexol-injection-challenging-652-million-market 2025-11-14T01:22:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/amneal-secures-fda-approval-for-first-generic-iohexol-injection-challenging-652-million-market 2025-11-14T01:22:31+00:00 hourly 0.9 https://trial.medpath.com/news/magnetic-microrobots-successfully-navigate-blood-vessels-for-targeted-drug-delivery-in-large-animal-studies 2025-11-14T01:22:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/magnetic-microrobots-successfully-navigate-blood-vessels-for-targeted-drug-delivery-in-large-animal-studies 2025-11-14T01:22:24+00:00 hourly 0.9 https://trial.medpath.com/news/iraq-launches-major-cancer-drug-manufacturing-initiative-with-50-price-reduction-target 2025-11-14T01:22:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/iraq-launches-major-cancer-drug-manufacturing-initiative-with-50-price-reduction-target 2025-11-14T01:22:21+00:00 hourly 0.9 https://trial.medpath.com/news/merck-acquires-cidara-therapeutics-for-9-2-billion-to-advance-revolutionary-flu-prevention-drug 2025-11-14T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/merck-acquires-cidara-therapeutics-for-9-2-billion-to-advance-revolutionary-flu-prevention-drug 2025-11-14T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/delve-bio-s-metagenomic-sequencing-test-shows-promise-for-faster-meningitis-encephalitis-diagnosis 2025-11-14T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/delve-bio-s-metagenomic-sequencing-test-shows-promise-for-faster-meningitis-encephalitis-diagnosis 2025-11-14T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/integra-lifesciences-receives-fda-510-k-clearance-for-cusa-clarity-ultrasonic-surgical-aspirator-system-in-cardiac-surgery 2025-11-13T21:31:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/integra-lifesciences-receives-fda-510-k-clearance-for-cusa-clarity-ultrasonic-surgical-aspirator-system-in-cardiac-surgery 2025-11-13T21:31:49+00:00 hourly 0.9 https://trial.medpath.com/news/salarius-pharmaceuticals-and-decoy-therapeutics-complete-strategic-merger-to-advance-ai-driven-peptide-conjugate-platform 2025-11-13T21:29:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/salarius-pharmaceuticals-and-decoy-therapeutics-complete-strategic-merger-to-advance-ai-driven-peptide-conjugate-platform 2025-11-13T21:29:28+00:00 hourly 0.9 https://trial.medpath.com/news/breakthrough-antibody-marv16-shows-40-100-fold-increased-potency-against-marburg-virus 2025-11-13T21:26:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/breakthrough-antibody-marv16-shows-40-100-fold-increased-potency-against-marburg-virus 2025-11-13T21:26:49+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-fast-track-designation-to-fog-001-first-in-class-b-catenin-inhibitor-for-desmoid-tumors 2025-11-13T21:26:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-fast-track-designation-to-fog-001-first-in-class-b-catenin-inhibitor-for-desmoid-tumors 2025-11-13T21:26:36+00:00 hourly 0.9 https://trial.medpath.com/news/eureka-s-artemis-car-t-cells-demonstrate-16-fold-superior-tumor-infiltration-in-neuroblastoma-study 2025-11-13T21:26:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eureka-s-artemis-car-t-cells-demonstrate-16-fold-superior-tumor-infiltration-in-neuroblastoma-study 2025-11-13T21:26:09+00:00 hourly 0.9 https://trial.medpath.com/news/legend-biotech-opens-31000-square-foot-r-d-facility-in-philadelphia-to-advance-car-t-cell-therapy-innovation 2025-11-13T21:25:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/legend-biotech-opens-31000-square-foot-r-d-facility-in-philadelphia-to-advance-car-t-cell-therapy-innovation 2025-11-13T21:25:56+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approved-prostate-cancer-drugs-show-promise-against-acute-myeloid-leukemia-in-preclinical-studies 2025-11-13T21:25:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approved-prostate-cancer-drugs-show-promise-against-acute-myeloid-leukemia-in-preclinical-studies 2025-11-13T21:25:17+00:00 hourly 0.9 https://trial.medpath.com/news/korro-bio-abandons-lead-rna-editing-drug-after-clinical-disappointment-cuts-34-of-staff 2025-11-13T21:23:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/korro-bio-abandons-lead-rna-editing-drug-after-clinical-disappointment-cuts-34-of-staff 2025-11-13T21:23:56+00:00 hourly 0.9 https://trial.medpath.com/news/zealand-pharma-halts-obesity-drug-dapiglutide-development-amid-crowded-glp-1-market 2025-11-13T21:22:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/zealand-pharma-halts-obesity-drug-dapiglutide-development-amid-crowded-glp-1-market 2025-11-13T21:22:32+00:00 hourly 0.9 https://trial.medpath.com/news/hypoglycemia-therapeutics-market-shows-robust-pipeline-activity-with-16-molecules-in-development 2025-11-13T21:22:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hypoglycemia-therapeutics-market-shows-robust-pipeline-activity-with-16-molecules-in-development 2025-11-13T21:22:00+00:00 hourly 0.9 https://trial.medpath.com/news/pfizer-completes-10-billion-metsera-acquisition-to-enter-obesity-market-with-monthly-glp-1-portfolio 2025-11-13T21:21:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pfizer-completes-10-billion-metsera-acquisition-to-enter-obesity-market-with-monthly-glp-1-portfolio 2025-11-13T21:21:36+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-first-interchangeable-biosimilar-to-pertuzumab-for-her2-positive-breast-cancer 2025-11-13T21:20:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-first-interchangeable-biosimilar-to-pertuzumab-for-her2-positive-breast-cancer 2025-11-13T21:20:08+00:00 hourly 0.9 https://trial.medpath.com/news/day-one-biopharmaceuticals-acquires-mersana-therapeutics-for-129m-targeting-rare-cancer-treatment 2025-11-13T21:19:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/day-one-biopharmaceuticals-acquires-mersana-therapeutics-for-129m-targeting-rare-cancer-treatment 2025-11-13T21:19:53+00:00 hourly 0.9 https://trial.medpath.com/news/icotec-receives-fda-clearance-for-cmore-ct-system-expanding-blackarmor-carbon-peek-technology-to-cervicothoracic-spine 2025-11-13T21:19:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/icotec-receives-fda-clearance-for-cmore-ct-system-expanding-blackarmor-carbon-peek-technology-to-cervicothoracic-spine 2025-11-13T21:19:50+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-kura-oncology-s-komzifti-for-npm1-mutated-aml-with-competitive-safety-advantage 2025-11-13T17:30:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-kura-oncology-s-komzifti-for-npm1-mutated-aml-with-competitive-safety-advantage 2025-11-13T17:30:39+00:00 hourly 0.9 https://trial.medpath.com/news/gilead-s-investigational-hiv-single-tablet-regimen-meets-primary-endpoint-in-phase-3-artistry-1-trial 2025-11-13T17:29:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gilead-s-investigational-hiv-single-tablet-regimen-meets-primary-endpoint-in-phase-3-artistry-1-trial 2025-11-13T17:29:27+00:00 hourly 0.9 https://trial.medpath.com/news/isofol-medical-secures-european-patent-protection-for-cancer-drug-arfolitixorin-until-2043 2025-11-13T17:25:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/isofol-medical-secures-european-patent-protection-for-cancer-drug-arfolitixorin-until-2043 2025-11-13T17:25:07+00:00 hourly 0.9 https://trial.medpath.com/news/medicus-pharma-receives-uk-regulatory-approval-to-expand-phase-2-basal-cell-carcinoma-study 2025-11-13T17:24:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/medicus-pharma-receives-uk-regulatory-approval-to-expand-phase-2-basal-cell-carcinoma-study 2025-11-13T17:24:40+00:00 hourly 0.9 https://trial.medpath.com/news/day-one-biopharmaceuticals-acquires-mersana-therapeutics-for-285-million-to-advance-novel-adc-for-rare-cancer 2025-11-13T17:24:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/day-one-biopharmaceuticals-acquires-mersana-therapeutics-for-285-million-to-advance-novel-adc-for-rare-cancer 2025-11-13T17:24:23+00:00 hourly 0.9 https://trial.medpath.com/news/austrian-study-challenges-routine-tablet-crushing-for-stroke-patients-with-dysphagia 2025-11-13T17:21:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/austrian-study-challenges-routine-tablet-crushing-for-stroke-patients-with-dysphagia 2025-11-13T17:21:57+00:00 hourly 0.9 https://trial.medpath.com/news/aeon-biopharma-secures-22-million-funding-to-advance-botox-biosimilar-abp-450-development 2025-11-13T17:21:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aeon-biopharma-secures-22-million-funding-to-advance-botox-biosimilar-abp-450-development 2025-11-13T17:21:33+00:00 hourly 0.9 https://trial.medpath.com/news/aeon-biopharma-achieves-100-amino-acid-sequence-match-with-botox-in-biosimilar-development 2025-11-13T17:21:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aeon-biopharma-achieves-100-amino-acid-sequence-match-with-botox-in-biosimilar-development 2025-11-13T17:21:31+00:00 hourly 0.9 https://trial.medpath.com/news/withings-receives-fda-clearance-for-beamo-multi-function-health-device-combining-ecg-stethoscope-and-thermometer 2025-11-13T17:20:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/withings-receives-fda-clearance-for-beamo-multi-function-health-device-combining-ecg-stethoscope-and-thermometer 2025-11-13T17:20:31+00:00 hourly 0.9 https://trial.medpath.com/news/century-therapeutics-unveils-immune-evasive-ipsc-beta-islet-therapy-for-type-1-diabetes 2025-11-13T17:20:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/century-therapeutics-unveils-immune-evasive-ipsc-beta-islet-therapy-for-type-1-diabetes 2025-11-13T17:20:16+00:00 hourly 0.9 https://trial.medpath.com/news/beacon-biosignals-secures-86m-series-b-to-advance-ai-driven-brain-health-diagnostics 2025-11-13T17:20:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/beacon-biosignals-secures-86m-series-b-to-advance-ai-driven-brain-health-diagnostics 2025-11-13T17:20:14+00:00 hourly 0.9 https://trial.medpath.com/news/viagra-shows-promise-for-reversing-genetic-hearing-loss-through-nitric-oxide-pathway 2025-11-13T17:20:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/viagra-shows-promise-for-reversing-genetic-hearing-loss-through-nitric-oxide-pathway 2025-11-13T17:20:00+00:00 hourly 0.9 https://trial.medpath.com/news/ingenus-pharmaceuticals-launches-first-generic-version-of-premarin-tablets-after-fda-approval 2025-11-13T17:19:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ingenus-pharmaceuticals-launches-first-generic-version-of-premarin-tablets-after-fda-approval 2025-11-13T17:19:52+00:00 hourly 0.9 https://trial.medpath.com/news/inflammasome-therapeutics-partners-with-mass-general-s-healey-als-center-to-test-novel-neuroinflammation-drug-k9 2025-11-13T17:19:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/inflammasome-therapeutics-partners-with-mass-general-s-healey-als-center-to-test-novel-neuroinflammation-drug-k9 2025-11-13T17:19:00+00:00 hourly 0.9 https://trial.medpath.com/news/traditional-chinese-medicine-flavonoid-extract-shows-promise-for-stroke-recovery-through-enhanced-angiogenesis 2025-11-13T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/traditional-chinese-medicine-flavonoid-extract-shows-promise-for-stroke-recovery-through-enhanced-angiogenesis 2025-11-13T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/phio-pharmaceuticals-achieves-100-tumor-clearance-in-skin-cancer-trial-as-fda-accepts-ph-762-development-protocol 2025-11-13T15:20:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/phio-pharmaceuticals-achieves-100-tumor-clearance-in-skin-cancer-trial-as-fda-accepts-ph-762-development-protocol 2025-11-13T15:20:00+00:00 hourly 0.9 https://trial.medpath.com/news/day-one-biopharmaceuticals-acquires-mersana-therapeutics-for-25-per-share-in-285-million-deal 2025-11-13T13:25:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/day-one-biopharmaceuticals-acquires-mersana-therapeutics-for-25-per-share-in-285-million-deal 2025-11-13T13:25:26+00:00 hourly 0.9 https://trial.medpath.com/news/zealand-pharma-reports-strong-q3-2025-results-as-obesity-drug-pipeline-approaches-key-data-readouts 2025-11-13T13:23:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/zealand-pharma-reports-strong-q3-2025-results-as-obesity-drug-pipeline-approaches-key-data-readouts 2025-11-13T13:23:45+00:00 hourly 0.9 https://trial.medpath.com/news/fda-accepts-itm-s-new-drug-application-for-177lu-edotreotide-in-gastroenteropancreatic-neuroendocrine-tumors 2025-11-13T13:23:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-accepts-itm-s-new-drug-application-for-177lu-edotreotide-in-gastroenteropancreatic-neuroendocrine-tumors 2025-11-13T13:23:09+00:00 hourly 0.9 https://trial.medpath.com/news/t-therapeutics-raises-91-million-series-a-to-advance-first-in-class-tcr-cd3-bispecifics-for-cancer-and-autoimmune-disease 2025-11-13T13:22:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/t-therapeutics-raises-91-million-series-a-to-advance-first-in-class-tcr-cd3-bispecifics-for-cancer-and-autoimmune-disease 2025-11-13T13:22:05+00:00 hourly 0.9 https://trial.medpath.com/news/adicon-acquires-crown-bioscience-for-204-million-to-create-global-laboratory-services-platform 2025-11-13T13:22:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/adicon-acquires-crown-bioscience-for-204-million-to-create-global-laboratory-services-platform 2025-11-13T13:22:00+00:00 hourly 0.9 https://trial.medpath.com/news/zydus-amplitude-s-robotic-surgical-system-andy-receives-ce-mark-approval-for-european-market 2025-11-13T13:20:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/zydus-amplitude-s-robotic-surgical-system-andy-receives-ce-mark-approval-for-european-market 2025-11-13T13:20:31+00:00 hourly 0.9 https://trial.medpath.com/news/scripta-therapeutics-raises-12m-to-target-transcription-factors-for-disease-modifying-therapies 2025-11-13T13:19:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/scripta-therapeutics-raises-12m-to-target-transcription-factors-for-disease-modifying-therapies 2025-11-13T13:19:52+00:00 hourly 0.9 https://trial.medpath.com/news/envirogold-global-achieves-99-55-gold-recovery-in-phase-3-metallurgical-testing-of-mine-tailings-reprocessing-technology 2025-11-13T13:19:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/envirogold-global-achieves-99-55-gold-recovery-in-phase-3-metallurgical-testing-of-mine-tailings-reprocessing-technology 2025-11-13T13:19:50+00:00 hourly 0.9 https://trial.medpath.com/news/mursla-bio-partners-with-global-pharma-to-develop-ai-driven-biomarkers-for-mash-precision-medicine 2025-11-13T13:19:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mursla-bio-partners-with-global-pharma-to-develop-ai-driven-biomarkers-for-mash-precision-medicine 2025-11-13T13:19:36+00:00 hourly 0.9 https://trial.medpath.com/news/charm-therapeutics-advances-ai-discovered-menin-inhibitor-chm-029-to-overcome-aml-drug-resistance 2025-11-13T12:12:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/charm-therapeutics-advances-ai-discovered-menin-inhibitor-chm-029-to-overcome-aml-drug-resistance 2025-11-13T12:12:00+00:00 hourly 0.9 https://trial.medpath.com/news/low-dose-colchicine-shows-promise-in-reducing-heart-attacks-and-strokes-in-cardiovascular-disease-patients 2025-11-13T09:23:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/low-dose-colchicine-shows-promise-in-reducing-heart-attacks-and-strokes-in-cardiovascular-disease-patients 2025-11-13T09:23:49+00:00 hourly 0.9 https://trial.medpath.com/news/revolutionary-nanoplatforms-combine-ferroptosis-and-immunotherapy-to-transform-tumor-microenvironment 2025-11-13T09:22:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/revolutionary-nanoplatforms-combine-ferroptosis-and-immunotherapy-to-transform-tumor-microenvironment 2025-11-13T09:22:50+00:00 hourly 0.9 https://trial.medpath.com/news/neoadjuvant-cemiplimab-plus-sbrt-improves-2-year-disease-free-survival-in-resectable-hepatocellular-carcinoma 2025-11-13T09:22:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/neoadjuvant-cemiplimab-plus-sbrt-improves-2-year-disease-free-survival-in-resectable-hepatocellular-carcinoma 2025-11-13T09:22:47+00:00 hourly 0.9 https://trial.medpath.com/news/rage-biotech-raises-a-29-million-series-a-to-advance-rna-therapeutics-for-chronic-inflammatory-diseases 2025-11-13T09:22:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rage-biotech-raises-a-29-million-series-a-to-advance-rna-therapeutics-for-chronic-inflammatory-diseases 2025-11-13T09:22:10+00:00 hourly 0.9 https://trial.medpath.com/news/korro-bio-s-rna-editing-drug-shows-promise-but-falls-short-of-efficacy-targets-in-alpha-1-antitrypsin-deficiency-trial 2025-11-13T05:23:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/korro-bio-s-rna-editing-drug-shows-promise-but-falls-short-of-efficacy-targets-in-alpha-1-antitrypsin-deficiency-trial 2025-11-13T05:23:21+00:00 hourly 0.9 https://trial.medpath.com/news/nhs-approves-glofitamab-for-earlier-treatment-of-aggressive-blood-cancer 2025-11-13T05:20:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nhs-approves-glofitamab-for-earlier-treatment-of-aggressive-blood-cancer 2025-11-13T05:20:28+00:00 hourly 0.9 https://trial.medpath.com/news/apellis-reports-5-year-data-showing-syfovre-delays-geographic-atrophy-progression-by-1-5-years 2025-11-13T01:27:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/apellis-reports-5-year-data-showing-syfovre-delays-geographic-atrophy-progression-by-1-5-years 2025-11-13T01:27:11+00:00 hourly 0.9 https://trial.medpath.com/news/health-canada-approves-kyzatrex-oral-testosterone-therapy-expanding-treatment-options-for-canadian-men 2025-11-13T01:23:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/health-canada-approves-kyzatrex-oral-testosterone-therapy-expanding-treatment-options-for-canadian-men 2025-11-13T01:23:57+00:00 hourly 0.9 https://trial.medpath.com/news/wrn-inhibitors-enter-clinical-development-phase-as-precision-oncology-market-expands 2025-11-13T01:23:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/wrn-inhibitors-enter-clinical-development-phase-as-precision-oncology-market-expands 2025-11-13T01:23:39+00:00 hourly 0.9 https://trial.medpath.com/news/indero-develops-3-day-microdosing-method-to-accelerate-topical-drug-development-using-gene-expression-analysis 2025-11-13T01:23:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/indero-develops-3-day-microdosing-method-to-accelerate-topical-drug-development-using-gene-expression-analysis 2025-11-13T01:23:31+00:00 hourly 0.9 https://trial.medpath.com/news/macrogenics-halts-lorigerlimab-development-in-prostate-cancer-secures-75m-in-partnership-proceeds 2025-11-13T01:21:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/macrogenics-halts-lorigerlimab-development-in-prostate-cancer-secures-75m-in-partnership-proceeds 2025-11-13T01:21:17+00:00 hourly 0.9 https://trial.medpath.com/news/eupraxia-s-ep-104gi-shows-sustained-clinical-remission-in-eosinophilic-esophagitis-patients-at-52-weeks 2025-11-13T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eupraxia-s-ep-104gi-shows-sustained-clinical-remission-in-eosinophilic-esophagitis-patients-at-52-weeks 2025-11-13T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-accelerated-approval-for-semaglutide-in-mash-treatment-but-equity-gaps-persist-in-clinical-trials 2025-11-13T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-accelerated-approval-for-semaglutide-in-mash-treatment-but-equity-gaps-persist-in-clinical-trials 2025-11-13T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/bristol-myers-squibb-and-sarah-cannon-research-institute-expand-strategic-collaboration-to-accelerate-cancer-clinical-trials 2025-11-12T21:29:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bristol-myers-squibb-and-sarah-cannon-research-institute-expand-strategic-collaboration-to-accelerate-cancer-clinical-trials 2025-11-12T21:29:57+00:00 hourly 0.9 https://trial.medpath.com/news/genezen-partners-with-humane-genomics-to-manufacture-novel-oncolytic-virus-therapy-for-pediatric-liver-cancer 2025-11-12T21:26:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/genezen-partners-with-humane-genomics-to-manufacture-novel-oncolytic-virus-therapy-for-pediatric-liver-cancer 2025-11-12T21:26:41+00:00 hourly 0.9 https://trial.medpath.com/news/lupin-manufacturing-solutions-launches-dedicated-oncology-block-at-vizag-facility-to-expand-cdmo-capabilities 2025-11-12T21:23:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lupin-manufacturing-solutions-launches-dedicated-oncology-block-at-vizag-facility-to-expand-cdmo-capabilities 2025-11-12T21:23:34+00:00 hourly 0.9 https://trial.medpath.com/news/federal-cannabis-crackdown-validates-mmj-international-s-fda-compliant-pharmaceutical-approach 2025-11-12T21:23:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/federal-cannabis-crackdown-validates-mmj-international-s-fda-compliant-pharmaceutical-approach 2025-11-12T21:23:17+00:00 hourly 0.9 https://trial.medpath.com/news/trinity-college-dublin-develops-needle-free-nasal-vaccine-that-blocks-whooping-cough-transmission 2025-11-12T21:22:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/trinity-college-dublin-develops-needle-free-nasal-vaccine-that-blocks-whooping-cough-transmission 2025-11-12T21:22:48+00:00 hourly 0.9 https://trial.medpath.com/news/modulight-biotherapeutics-raises-12-2m-to-advance-optogenetic-therapy-for-neurological-disorders 2025-11-12T21:22:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/modulight-biotherapeutics-raises-12-2m-to-advance-optogenetic-therapy-for-neurological-disorders 2025-11-12T21:22:19+00:00 hourly 0.9 https://trial.medpath.com/news/abbvie-terminates-3-5-billion-calico-partnership-after-11-years-cuts-100-jobs 2025-11-12T21:21:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/abbvie-terminates-3-5-billion-calico-partnership-after-11-years-cuts-100-jobs 2025-11-12T21:21:49+00:00 hourly 0.9